Ethereum price to increase by 12% in 2024

In the ever-evolving landscape of cryptocurrency, Ethereum stands out as a beacon of potential and innovation. As we delve into the intricacies of its market dynamics, recent analyses and expert forecasts suggest a promising horizon for Ethereum in 2024, with an anticipated price increase of 12%. This news not only captivates the attention of investors and enthusiasts alike but also marks a significant moment in the digital currency sphere.

Ethereum: A Brief Overview

Before we explore the factors contributing to this optimistic projection, let’s briefly revisit what Ethereum is and why it holds such a pivotal role in the cryptocurrency world. Ethereum, launched in 2015 by Vitalik Buterin and his team, is not just a cryptocurrency; it’s a decentralized platform that enables developers to build and deploy smart contracts and decentralized applications (DApps) without the risks of fraud, downtime, or interference from a third party. Its native currency, Ether (ETH), powers transactions on the platform, serving as a fuel for the decentralized applications it hosts.

Factors Driving Ethereum’s Price Increase

Several key factors are contributing to the anticipated 12% price increase of Ethereum in 2024. These include:

  1. Increased Adoption of DeFi: Decentralized Finance (DeFi) has been a major catalyst for Ethereum’s growth. As more financial applications and services are built on the Ethereum network, the demand for ETH increases, driving up its price.
  2. Ethereum 2.0 Upgrade: The transition to Ethereum 2.0, or Eth2, marks a significant upgrade to the network’s infrastructure, shifting from a proof-of-work to a proof-of-stake consensus mechanism. This change is expected to enhance the network’s scalability, security, and sustainability, making it more attractive to users and investors.
  3. Institutional Interest: Institutional investment in Ethereum has been on the rise, with more financial institutions and corporations recognizing its potential as a store of value and an investment asset. This growing interest contributes to the bullish outlook for ETH.
  4. NFT Market Growth: The explosion of the Non-Fungible Token (NFT) market has directly impacted Ethereum, as the majority of NFT transactions are conducted on its blockchain. The increasing popularity of NFTs continues to drive demand for ETH.
  5. Global Economic Factors: Macroeconomic factors, including inflation rates and currency devaluation, have led investors to seek alternative stores of value. Cryptocurrencies like Ethereum offer a viable option, further fueling its price increase.

Challenges and Considerations

While the future looks promising for Ethereum, it’s important to acknowledge the challenges and uncertainties that lie ahead. The cryptocurrency market is notoriously volatile, and external factors such as regulatory changes, technological advancements, and market sentiment can significantly impact price movements. Investors should conduct thorough research and consider their risk tolerance before entering the market.

Conclusion

The anticipated 12% increase in Ethereum’s price in 2024 is a testament to its growing significance in the digital economy. With its robust platform for decentralized applications, ongoing upgrades, and increasing adoption across various sectors, Ethereum is well-positioned for continued growth. However, potential investors should remain vigilant, keeping an eye on market trends and developments in the cryptocurrency world.

As we look towards a future where digital currencies play a pivotal role in our financial systems, Ethereum’s journey offers a fascinating glimpse into the potential of blockchain technology and decentralized finance. The road ahead is filled with opportunities and challenges alike, making Ethereum a key player to watch in the evolving narrative of cryptocurrency.

Immunocellular Therapeutics Targeting Cancer Stem Cells

Immunocellular Therapeutics Ltd. (OTCBB: IMUC) is a biopharmaceutical company focused on improving cancer treatments through new immune-based products. Unlike similar companies, such as ImmunoGen Inc. (NASDAQ: IMGN) and Dendreon Corp. (NASDAQ: DNDN), IMUC is developing immunotherapies that target cancer stem cells in addition to normal cancer cells as a means to delay and prevent cancer recurrence.

The Fight Against Cancer Recurrence

Cancer recurrence is simply the return of cancer after a period of remission. Cancer recurrence can be local (in the same place), regional (in lymph nodes), or distant (metastasized) in relation to the location of the original cancer. According to the American Cancer Society, about 10% to 20% of all cancer patients experience recurrence, typically within the first three to five years after initial treatment. However, in more aggressive cancers, such as glioblastoma multiforme (GBM), a common form of brain cancer, tumors eventually recur in every patient, usually within less than a year.

What are Cancer Stem Cells?

Stem cells have the remarkable ability to develop into many different types of cells in the body during early life and growth. Moreover, they can serve as an internal repair system, dividing without limit to replenish other cells. When a stem cell divides, the new cell can either remain a stem cell or become a more specialized cell.

Conventional cancer treatments can eliminate cancer cells, but cancer stem cells have been shown to be more resistant to chemotherapy and radiation. Even a few remaining cancer stem cells can continue to replicate and cause recurrence.

IMUC’s Cancer Immunotherapy ICT-107

IMUC has developed a unique treatment that targets cancer stem cells. In a Phase I study with GBM patients, the company’s lead product ICT-107 resulted in a median cancer remission time of 16.9 months.  The disease-free rate for the current standard of care, radiation and chemotherapy, is only 6.9 months. Six of the 16 patients in the trial remain free of disease after more than three years. More importantly, the three-year survival rate was 55% compared to 16% for historical controls.

In early 2011, IMUC began a Phase II trial with ICT-107 in patients with newly diagnosed GBM. The double-blind, placebo-controlled, randomized clinical trial will enroll approximately 160 patients at more than 20 sites around the U.S.  Enrollment is more than half completed, and the company expects to finish in Q2 2012. Management anticipates an interim analysis by the end of 2012 and final results near the end of 2013.

A Great Investment Opportunity

There’s growing evidence that cancer stem cells contribute to tumor recurrence, and IMUC’s cancer immunotherapy (ICT-107), which effectively targets cancer stem cells, has had very promising results in patients.

IMUC is not alone in believing that targeting cancer stem cells can significantly delay cancer recurrence. Verastem, a private biopharmaceutical company, backed by well-known venture capitalists, including MPM Capital and Bessemer Venture Partners, is also developing drugs that target cancer stem cells. Verastem has been able to raise almost $50 million and recently filed an S-1 for a proposed IPO.

IMUC management recently completed a financing round, increasing the company’s cash balance to over $15 million. The capital raise ensures enough money to last until the end of the Phase II study and funds additional studies in ovarian cancer and recurrent GBM. With a market capitalization of just $42 million, IMUC appears to be significantly undervalued compared to similar companies.

HEXO Corp announces $70 million private placement of convertible debentures led by Directors, CEO, and long-term shareholders; reschedules FY 2019 earnings call

GATINEAU, Quebec, Oct. 23, 2019 (GLOBE NEWSWIRE) — HEXO Corp (“HEXO” or the “Company”) (TSX:HEXO; NYSE:HEXO) today announced that it has entered into subscription agreements with a group of investors pursuant to which the investors have agreed to purchase, on a private placement basis, $70 million principal amount of 8.0% unsecured convertible debentures of the Company (the “Debentures”). The Company has also announced that in light of the financing and additional time required to finalize its year end filings, the Company has rescheduled the release of its fourth quarter and full year ended July 31, 2019 financial results to October 28, 2019 and its earnings call to discuss these results to 8:30 a.m. EDT on Tuesday, October 29, 2019 (details below). All amounts are expressed in Canadian dollars.

The group of investors includes, but is not limited to, Sebastien St-Louis, CEO and co-founder of HEXO Corp, as well as Board members Dr. Michael Munzar, Vincent Chiara, Nathalie Bourque and Adam Miron.

“The confidence in HEXO Corp that this $70 million private placement demonstrates is a testament to the value the Company is expected to bring to shareholders,” said Sebastien St-Louis, CEO and co-founder of HEXO Corp. “We remain focused on garnering significant market share, driving growth, and in shaping this company into a mature, resilient and valued leader in our industry.”

The Debentures will bear interest from the date of closing at 8.0% per annum payable quarterly and will mature on the date which is three years from issuance. Following the date which is one year from issuance, the Debentures will be convertible at the option of the holder into common shares of the Company at any time prior to maturity at a conversion price of $3.16 per share (the “Conversion Price”), subject to adjustment in certain events.

“It is important to note the one-year anti-dilution feature in this arrangement, meaning that the financing does not dilute current shareowners’ ownership of the Company in the short term,” added St-Louis.

Beginning on the date which is one year from issuance, the Company may force the conversion of all of the principal amount of the then outstanding Debentures at the Conversion Price on not less than 30 days’ notice should the daily volume weighted average trading price of the common shares of the Company be greater than $7.50 for any 15 consecutive trading days.

At any time on or before the date which is one year from issuance, the ‎Company may repay all, but not less than all, of the principal amount of the ‎Debentures, ‎plus accrued and unpaid interest. ‎

Upon any repayment of the principal amount of the Debentures, the ‎Company shall have the right to satisfy the repayment of the principal amount, ‎together with all accrued and unpaid interest thereon, through the conversion of ‎such amounts into common shares of the Company at the Conversion Price.‎

Upon a change of control of the Company, holders of the Debentures will have the right to require the Company to repurchase their Debentures, in whole or in part, on the date that is 30 days following the giving of notice of the change of control, at a price equal to 115% of the principal amount of the Convertible Debentures then outstanding plus accrued and unpaid interest thereon (the “Offer Price”). If 90% or more of the principal amount of the Convertible Debentures outstanding on the date of the notice of the change of control have been tendered for redemption, the Company will have the right to redeem all of the remaining Debentures at the Offer Price.

The Debentures and any common shares of the Company issuable upon conversion thereof will be subject to a statutory hold period lasting four months and one day following the closing date.

The Company intends to use the net proceeds of the private placement for working capital and general corporate purposes.

Closing of the Offering is expected to occur on or about November 15, 2019.  The private placement is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approvals of the Toronto Stock Exchange and the New York Stock Exchange.

It is anticipated that certain insiders of the Company will purchase approximately $8.676 million principal amount of the Debentures under the private placement. These purchases will be considered to be “related party transactions” pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company will be exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with the participation of these insiders in the private placement in reliance of sections 5.5(a) and 5.7(1)(a) of MI 61-101.

Webcast Details
Date: October 29, 2019
Time: 8:30 a.m. EDT
Webcast: https://event.on24.com/wcc/r/2112048/C13DC676CE53A5FD2CEB4095D0FF4A3A
Replay information: A replay of the call will be accessible by telephone until 11:59 a.m. EDT on November 12, 2019.
Toll Free Dial-In Number: 1-888-390-0541.
Replay Password: 531469#

About HEXO Corp

HEXO Corp is an award-winning consumer packaged goods cannabis company that creates and distributes innovative products to serve the global cannabis market. Through its hub and spoke business strategy, HEXO Corp is partnering with Fortune 500 companies, bringing its brand value, cannabinoid isolation technology, licensed infrastructure and regulatory expertise to established companies, leveraging their distribution networks and capacity. As one of the largest licensed cannabis companies in Canada, HEXO Corp operates with 2.4 million sq. ft of facilities in Ontario and Quebec. The Company is also expanding internationally and has a foothold in Greece to establish a Eurozone processing, production and distribution centre. The Company serves the Canadian adult-use markets under its HEXO Cannabis and Up Cannabis brands, and the medical market under HEXO medical cannabis. For more information please visit hexocorp.com.

Forward-Looking Statements

This press release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are based on certain expectations and assumptions and are subject to known and unknown risks and uncertainties and other factors that could cause actual events, results, performance and achievements to differ materially from those anticipated in these forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results. A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s Annual Information Form and other continuous disclosure filings, which are available on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.

Investor Relations:

Jennifer Smith

1-866-438-8429

invest@HEXO.com

www.hexocorp.com

Media Relations:

Caroline Milliard

(819) 317-0526

media@hexo.com

The post HEXO Corp announces $70 million private placement of convertible debentures led by Directors, CEO, and long-term shareholders; reschedules FY 2019 earnings call appeared first on CannabisFN.

Ravenquest Client Achieves Landmark Success: Bonify Sales License Fully Reinstated by Health Canada

VANCOUVER, British Columbia, Oct. 23, 2019 (GLOBE NEWSWIRE) — RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”), one of Canada’s most innovative cannabis producers, announces that, for the first time in the history of Canadian legal cannabis sales, its client, Bonify, has had its Health Canada license suspension lifted and sales license fully reinstated.

Following suspension of Bonify’s sales license in February 2019, RavenQuest’s services team led by CEO George Robinson (who also acted as interim CEO at Bonify) provided the necessary direction and corrective action to restore confidence with Health Canada and ultimately fully restore Bonify’s sales license.

Robinson commented by stating “we are very excited to see full reinstatement of the sales license to our client, Bonify.  Having guided Bonify through corrective action vis-a-vis operational procedures, proper record-keeping, training and all other standard operational procedures within the Bonify facility, we now have the roadmap to license reinstatement for non-compliant operators.  This is a landmark moment in an industry that has faced several high-profile compliance challenges.”

“The Canadian Cannabis industry needs new leadership that focusses upon doing things the right way.  The lessons from Bonify are clear:  Follow the rules, train your staff and run a clean, well designed facility capable of producing high quality cannabis without cutting corners.  RavenQuest’s consulting team has been inside over 50 licensed facilities.  We’ve seen it all.  Our mission has always been leadership in compliant, efficient and legal cannabis production.  Today’s license flip from ‘suspended’ to ‘reinstated’ represents a new direction for Bonify, for other non-compliant LP’s and for the industry as a whole.  A great day for Canadian cannabis,” Robinson continued.

Bonify’s sales license was suspended by Health Canada in February 2019 following non-compliance which occurred within the company in 2018.

RavenQuest was retained by Bonify in late 2018 to provide operational direction and oversight to Bonify’s 320,000 square foot cannabis production facility located in Winnipeg, Manitoba.  RavenQuest CEO, George Robinson, took the helm as acting CEO of Bonify in early 2019.  RavenQuest has a lengthy history as a leading consultant in the Canadian cannabis space, and was retained for the purposes of restoring compliance with Health Canada regulations and improving and streamlining production operations.

For more information, access RavenQuest’s investor presentation, fact sheet and videos here.

Follow RavenQuest:
Twitter
Instagram
Facebook
LinkedIn

About RavenQuest BioMed Inc.

RavenQuest is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.

RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant.  The Company also focuses on partnerships with Indigenous communities.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact: Mathieu McDonald, Corporate Communications
1-877-282-1586

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

The post Ravenquest Client Achieves Landmark Success: Bonify Sales License Fully Reinstated by Health Canada appeared first on CannabisFN.

Pure Global Receives License to Sell Extracts, Topicals, and Edibles

TORONTO, Oct. 24, 2019 /CNW/ – Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF) (the “Company” or “Pure Global” or “Pure“), an integrated growth-oriented cannabis bulk extracts and consumer products manufacturing company, operating through its wholly-owned subsidiary PureSinse Inc., a Health Canada Licensed Producer under the Cannabis Act, is pleased to announce it has received an amendment to its processing license to allow the sale of extracts, topicals, and edibles to medical and legal adult consumer markets.

Receiving this license is timely as the Company recently received its oil sales license enabling it to significantly broaden its product offerings to medical and recreational consumers in the high margin concentrate categories. With the approval to produce and sell extracts, topicals, and edibles, the Company can introduce a full line of premium quality branded and white label cannabis and cannabidiol (“CBD”) products including vape pens, which have been formulated without harmful chemicals, pre-formulated oils, extracts, topicals, and edibles. The Company has submitted 20 SKUs to Health Canada for release as early as December this year and plans on submitting more in the coming months as it expands its product lines in high-margin categories.

Pure Global anticipates receipt of Health Canada approval soon to add over 10,000 square feet of finished eu-GMP grade manufacturing space, comprised of 12 cultivation, processing, and extraction rooms to the Company’s already licensed site. Once the approvals are obtained, the Company can commence activities to enable the sale of bulk concentrates, branded and white label medical, recreational, and wellness products, and co-manufacturing and tolling services.

“Our consumer and B2B brands have been developed to take full advantage of cannabis derivative products. Receiving this license is a big step for Pure”, said Pure Global CEO & President, Malay Panchal. “We have the equipment in place to provide premium cannabis extracts, topicals, and edibles for consumers and companies looking for the highest quality products. We have worked very hard to put in place an organizational structure that will create significant value for our shareholders. This licensing approval is significant step in our journey as it allows us to participate in the newly released edibles and concentrates regulations that went into effect October 17, 2019,” added Mr. Panchal.

About Pure Global Cannabis

Pure Global is a eu-GMP grade cannabis manufacturer focused on producing high-quality high margin branded and white label cannabis and CBD consumer products, premium quality bulk dried flower, full spectrum concentrates, and pre-formulated active ingredients for CPG manufacturers globally. The Company is led by a professional team of experienced pharma, biotechnology, horticultural, extraction, manufacturing and consumer packaged goods experts, and operates through its wholly owned subsidiary, PureSinse Inc., which is a licensed producer under the Cannabis Act. Pure operates a B2B brand under PureCanna Solutions which is focused on high-margin bulk cannabis extracts, bulk CBD sales, as well as white label, and co-manufacturing services. The Company’s 18,000 square foot Brampton manufacturing campus houses facilities for vertically farmed hydroponic indoor cultivation, R&D, extraction, processing, and packaging. To compete in international markets, Pure Global is the process of deploying a joint operation in Yunnan, China for large scale hemp derived organic bulk CBD manufacturing and processing for international bulk and finished product sale under Special Economic Zone tax-free export provisions. Pure has also launched, or is in the process of launching, several premium branded products in targeted consumer categories into the Canadian legal adult market including PureSinse® Wellness, Paper&Weed Pre-Rolls, Galaxy Cannabis, Kumo Edibles, and PureSinse® Medical, which operates with Pure’s wholly own subsidiary Spark Cannabis Clinic, offering free telemedicine consultation for medical cannabis patients across Canada. Through its recently acquired division, The Great Canadian Health Company®, which won Hemp Product Company of the year at the recent 2019 GrowUp Awards, Pure is launching a line of organic hemp oil and CBD topical products, into several markets in Europe and Asia in early 2020.

FORWARD-LOOKING STATEMENTS

This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global’s future plans and intentions. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

To register to Pure Global’s mailing list, please visit www.pureglobal.com. Follow @pureglobalcanna on Twitter and Facebook and @pureglobalcannabis on Instagram.

SOURCE Pure Global Cannabis Inc.

For further information: Stephen Pynn, VP Corporate Development, Telephone: 1-866-840-PURE (7873), E-mail: stephen@pureglobal.com; Malay (Mel) Panchal, President & CEO, Telephone: 1-866-840-PURE (7873), E-mail: info@pureglobal.com

The post Pure Global Receives License to Sell Extracts, Topicals, and Edibles appeared first on CannabisFN.

THC BioMed Now Licensed to Sell Edibles, Topicals and Extracts

VANCOUVER, Oct. 24, 2019 /CNW/ – THC BioMed Intl Ltd. (“THC BioMed“) (CSE: THC) announces that Health Canada has amended its licence to authorize the sale of cannabis extracts, topicals and edibles.

The Canadian market for cannabis edibles, topicals and extracts is worth an estimated $2.7 billion per year, with edibles representing more than half that amount, according to a report from Deloitte in May 2019. This spending is expected to be in addition to the approximately $6 billion estimated domestic market for recreational and medical cannabis.

While Health Canada has indicated that sale of these newly legalized products will not be made available to the public until at least mid-December, THC has completed renovations of their flagship Acland Road location to enable production of these products. THC BioMed now has a total of 22 strata lots licensed for production.

THC BioMed expects to start building inventory soon and looks forward to being able to provide the same high quality products to customers in extract, topical and edible form.

About THC

THC is an ACMPR Licensed Producer and Canada’s largest supplier of legal Cannabis Genetics. THC is on the leading edge of scientific research and the development of products and services related to the medical cannabis industry. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry. Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com

Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed.  Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed.  In some cases, you can identify forward-looking statements by the use of words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions.  Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that (a) the Canadian market for cannabis edibles, topicals and extracts is worth an estimated $2.7 billion per year and the other market projections from Deloitte’s report will be relized, (b) THC expects to start building inventory soon and looks forward to being able to provide the same high quality products to customers in extract, topical and edible form and (c) THC will be on the forefront of this rapidly growing industry. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

SOURCE THC BioMed

For further information: President and CEO: John Miller, THC Biomed Intl Ltd., T: 1-844-THCMEDS, E: info@thcbiomed.com

Related Links

http://thcbiomed.com/

The post THC BioMed Now Licensed to Sell Edibles, Topicals and Extracts appeared first on CannabisFN.

A Choom Investment Holding Receives Two Production and Processing Licenses from Health Canada

VANCOUVER, Oct. 24, 2019 /CNW/ – Choom™ (CSE: CHOO; OTCQB: CHOOF), an emerging adult use cannabis company that has secured one of the largest national retail networks in Canada, is pleased to announce that Sitka Weedworks (formerly Specialty Medijuana Products Inc.), of which Choom is 9.8% equity stakeholder, has received two production and processing licenses from Health Canada. These licenses allow for the production and sale of a wide range of cannabis products, including dried flower, pre-rolls, oils, capsules, edibles, vaporizer pens, and more. Sitka Weedworks is currently producing 2,200 plants in its production facilities, with plans to lease additional cultivation spaces to 53 cannabis micro-cultivators. This micro-cultivator platform will be among the first in Canada to deliver small-batch craft cannabis to the legal market.

Additionally, Choom is pleased to acknowledge a proposed change in British Columbia’s regulatory system concerning the direct sale of cannabis products by licensed producers (“Farm-Gate Sales”). Comments made by B.C. Solicitor General Mike Farnsworth have set the stage for the approval of Farm-Gate Sales in British Columbia, though the expected timeline of these changes is not defined.

Say hello to Choom™
Choom™ is an emerging adult use cannabis company whose mission is to establish one of the largest retail networks in Canada. The Choom brand is inspired by Hawaii’s “Choom Gang”—a group of buddies in Honolulu during the 1970’s who loved to smoke weed—or as the locals called it, “Choom”. Evoking the spirit of the original Choom Gang, our brand caters to the Canadian adult use market with the ethos of ‘cultivating good times’. Choom™ is focused on delivering an elevated customer experience through our curated retail environments, offering a diversity of brands for Canadians across a national retail network.

“Corey Gillon”
President

Cautionary Statement:

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking information          
This news release contains forward-looking information relating to the Company’s proposed activities and other statements that are not historical facts. Forward-looking information relates to management’s future outlook and anticipated events or results, and include statements or information regarding the future plans or prospects of the Company. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. These factors include risks and uncertainties associated with or arising as a result of delays in obtaining or an inability to obtain required regulatory approvals, access to sufficient quantities of cannabis, the results of diligence investigations, the actions of third parties, the results of negotiations with third parties, developments in the cannabis sector, the ability to access sufficient capital from internal and external sources, reliance on key personnel, regulatory risks and delays and other risks and uncertainties discussed in the management discussion and analysis section of the Company’s interim and most recent annual financial statement or other reports and filings, including those made with the CSE and applicable Canadian securities regulators. There can be no assurance that such forward looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information.

SOURCE Choom Holdings Inc.

For further information: Choom Holdings Inc.: Corey Gillon, President, T: 604.683.2509, F: 604.683.2506, E: corey@choom.ca; Chris Bogart, CEO, T: 604.683.2509, F: 604.683.2506, E: chris@choom.ca

Related Links

https://choom.ca/

The post A Choom Investment Holding Receives Two Production and Processing Licenses from Health Canada appeared first on CannabisFN.

Innovative Industrial Properties Acquires Florida Property and Expands Real Estate Partnership with Trulieve Cannabis Corp.

SAN DIEGO–(BUSINESS WIRE)–Innovative Industrial Properties, Inc. (IIP), the first and only real estate company on the New York Stock Exchange (NYSE: IIPR) focused on the regulated U.S. cannabis industry, announced today that it closed on the acquisition of a property in Quincy, Florida, which comprises five buildings totaling approximately 120,000 square feet of industrial space, from Trulieve Cannabis Corp. (Trulieve), a leading and top-performing cannabis company in the United States (CSE: TRUL & OTC: TCNNF).

“It is great to team with IIP again on this transaction, providing us the real estate capital to continue to expand our capacity in one of the largest and most dynamic medical cannabis markets in the United States”

Tweet this

Concurrent with the closing of the purchase, IIP entered into a triple-net lease agreement with a subsidiary of Trulieve, for continued operation as a licensed medical cannabis cultivation facility. The purchase price for the Florida property was $17.0 million (excluding transaction costs). The initial lease term is ten years, with two options to extend the term of the lease for five years each. The initial annualized base rent is equal to 11% of the purchase price for the property. Earlier this year, IIP executed a sale-leaseback transaction with Trulieve for a 150,000 square foot industrial facility in Holyoke, Massachusetts for an initial purchase price of $3.5 million (excluding transaction costs), pursuant to which Trulieve is expected to complete tenant improvements for the building, for which IIP has agreed to provide reimbursement of up to $40.0 million.

As the pioneering real estate investment trust (REIT) for the medical-use cannabis industry, IIP partners with experienced medical-use cannabis operators and serves as a source of capital by acquiring and leasing back their real estate assets, in addition to offering other creative real estate-based capital solutions.

“By its consistent dedication to patient-centric values from day one, Trulieve has become the preeminent operator in Florida, and we are thrilled to partner with them again on this project as a long-term real estate partner,” said Paul Smithers, President and Chief Executive Officer of IIP. “Within a few short years, the Florida medical cannabis market has witnessed remarkable growth, and Trulieve has played an invaluable role in the market by meeting that patient need.”

Trulieve is a publicly traded Canadian company and multi-state cannabis operator employing approximately 2,700 people with licenses in Florida, Massachusetts, California and Connecticut.

“It is great to team with IIP again on this transaction, providing us the real estate capital to continue to expand our capacity in one of the largest and most dynamic medical cannabis markets in the United States,” said Kim Rivers, Chief Executive Officer of Trulieve. “These newly-developed cultivation facilities provide us with the optimal controlled environments to continue to deliver the highest quality products to patients throughout the state of Florida.”

Florida represents one of the largest and one of the fastest growing medical-use cannabis markets in the United States. Floridians overwhelmingly supported the passage of the medical-use cannabis program in 2016 with 71% voter approval. Qualifying medical conditions for the program include, among others, cancer, epilepsy, PTSD, HIV/AIDS and multiple sclerosis. Smokable flower was initially banned; however, a bill removing the prohibition was signed into law in March 2019. According to the Florida Office of Medical Marijuana Use (OMMU), as of October 11, 2019, there were over 270,000 qualified patients and over 2,500 qualified physicians in the medical-use cannabis program.

As of October 23, 2019, IIP owned 35 properties located in Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota, New York, Nevada, Ohio and Pennsylvania, totaling approximately 2.6 million rentable square feet (including approximately 832,000 rentable square feet under development/redevelopment), which were 100% leased with a weighted-average remaining lease term of approximately 15.6 years. As of October 23, 2019, IIP had invested approximately $371.6 million in the aggregate (excluding transaction costs) and had committed an additional approximately $133.0 million to reimburse certain tenants and sellers for completion of construction and tenant improvements at IIP’s properties. IIP’s average current yield on invested capital is approximately 13.8% for these 35 properties, calculated as (a) the sum of the current base rents, supplemental rent (with respect to the lease with PharmaCann LLC at one of IIP’s New York properties) and property management fees (after the expiration of applicable base rent abatement or deferral periods), divided by (b) IIP’s aggregate investment in these properties (excluding transaction costs and including aggregate potential development/redevelopment funding and tenant reimbursements of approximately $133.0 million). These statistics do not include up to $40.0 million that may be funded in the future pursuant to IIP’s lease with Trulieve at one of IIP’s Massachusetts properties, the additional $4.0 million which may be requested by PharmaCann LLC at one of IIP’s Pennsylvania properties or $2.0 million that may be funded in the future pursuant to IIP’s lease with Holistic Industries, Inc. at one of IIP’s Massachusetts properties, as the tenants at those properties may not elect to have IIP disburse those funds to them and pay IIP the corresponding base rent on those funds.

About Innovative Industrial Properties

Innovative Industrial Properties, Inc. is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated medical-use cannabis facilities. Innovative Industrial Properties, Inc. has elected to be taxed as a real estate investment trust, commencing with the year ended December 31, 2017. Additional information is available at www.innovativeindustrialproperties.com.

Innovative Industrial Properties Forward-Looking Statements

This press release contains statements that IIP believes to be “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than historical facts, including, without limitation, statements regarding the lease of the Florida property, Trulieve and the Florida regulated cannabis market, are forward-looking statements. When used in this press release, words such as we “expect,” “intend,” “plan,” “estimate,” “anticipate,” “believe” or “should” or the negative thereof or similar terminology are generally intended to identify forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. Investors should not place undue reliance upon forward-looking statements. IIP disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About Trulieve

Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve also operates in California, Massachusetts and Connecticut. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL.

Trulieve Forward-Looking Statements

This press release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of Trulieve. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of Trulieve to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although Trulieve believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, Trulieve assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States and may not be offered or sold within the United States (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements. To learn more about Trulieve, visit www.Trulieve.com.

The Canadian Securities Exchange has not reviewed, approved or disapproved the ‎content of this news release.‎

Contacts

IIP Contact:
Catherine Hastings
Chief Financial Officer, Chief Accounting Officer and Treasurer
Innovative Industrial Properties, Inc.
(858) 997-3332

Trulieve Contact:
Lynn Ricci
Director, Investor Relations
850-270-5691
IR@trulieve.com

The post Innovative Industrial Properties Acquires Florida Property and Expands Real Estate Partnership with Trulieve Cannabis Corp. appeared first on CannabisFN.

Avicanna (TSX: AVCN) Completes First Commercial Exports of CBD to South Africa and the United Kingdom

TORONTO, Oct. 24, 2019 /CNW/ – Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN)(OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of cannabinoid-based products, is pleased to announce that Santa Marta Golden Hemp S.A.S. (“SMGH“), its majority owned subsidiary, has completed commercial exports of its Aureus™ brand of CBD-based products to South Africa and the United Kingdom (collectively, the “Jurisdictions“).

The Aureus brand of products include an organic and sustainable line of plant-derived active pharmaceutical ingredients (“APIs“) and bulk CBD formulations developed by Avicanna in collaboration with SMGH and Sativa Nativa S.A.S. (“Sativa Nativa“), which is also a majority owned subsidiary of Avicanna. These initial sales included the export of CBD isolate and 4% bulk formulation for CBD oil sublingual sprays. Each of the above exports has been completed in accordance with all applicable laws in the Jurisdictions.

Aras Azadian, Avicanna’s Chief Executive Officer, stated “We are excited to bring the Aureus brand of cannabinoid APIs to our international customers. We believe these initial sales further validate the brand’s opportunities in these two countries, as well as the potential for us to actively market our APIs across the globe to manufacturers of CBD products. We believe the Aureus brand of API products will become a leader in organic and sustainable cannabinoid raw materials and the gold standard with respect to global quality controls, which we believe are necessary for the evolution of a worldwide cannabinoid industry.”

About Aureus

The Aureus brand is a collaboration between Avicanna and its two majority owned Colombian subsidiaries, SMGH and Sativa Nativa. It is expected that SMGH and Sativa Nativa will sell a range of premium of APIs, in the form of resins, distillates and isolates under the Aureus brand. These APIs are expected to consist of purified cannabinoids including cannabidiol (CBD), tetrahydrocannabinol (THC) and other rare cannabinoids. The Aureus brand will allow customers to have confidence that each shipment of API will meet Avicanna’s industry leading standards of quality, has been grown in accordance with Good Agricultural and Collection Practices and has been extracted in compliance with Good Manufacturing Standards. Additionally, Aureus products are cultivated with organic, environmentally sustainable and socially responsible practices.

About Avicanna

Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email info@avicanna.com.

Cautionary Note Regarding Forward-Looking Information and Statements

Certain information in this press release contains forward-looking statements. Such statements include but are not limited to the expected products to be marketed under the Aureus brand and expected manufacturing standards of the Aureus products. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict, including the risk factors set out under the heading “Risk Factors” in the Company’s long form final prospectus dated July 8, 2019. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements, unless and until required by securities laws applicable to the Company.

SOURCE Avicanna Inc.

Related Links

avicanna.com

The post Avicanna (TSX: AVCN) Completes First Commercial Exports of CBD to South Africa and the United Kingdom appeared first on CannabisFN.

Xtraction Services Announces Purchase of Shares in the Open Market by Archytas Ventures LLC

Not for Distribution to U.S. Newswire Servicers or For Dissemination in the United States

LOS ANGELES–(BUSINESS WIRE)–Xtraction Services Holding Corp., (“Xtraction Services”, “XS” or the “Company“) (CSE:XS), a fast-growing provider of equipment leasing solutions to owner/operators of cannabis and hemp companies in the United States, is pleased to announce that Archytas Ventures LLC (“Archytas”) (an investment company controlled by David Kivitz, CEO of XS and Antony Radbod, CMO of XS) purchased Common Shares (Subordinate Voting Shares being the listed class of shares) of Xtraction Services in the open market.

As of Wednesday, October 23, 2019, Archytas purchased a total of 274,500 Subordinate Voting Shares at an average price of CAD$0.2068. Assuming all outstanding Proportionate Voting Shares are converted into Subordinate Voting Shares, Archytas’ total ownership in Xtraction Services would be 11,434,075 Subordinate Shares or approximately 24%.

David Kivitz, Chief Executive Officer of XS, commented, “We are committed to building a quality leasing company that provides much needed financial support to the cannabis and hemp industry. We strongly believe in the value of the business and see tremendous growth potential ahead. Our current market capitalization does not appropriately reflect the true value of XS, nor does it take into consideration our future earning potential. Our recent purchase in the open market reinforces our commitment and belief in the viability of the Company.”

About Xtraction Services

Founded in 2017, XS specializes in providing equipment leasing solutions in the United States to owner/operators of cannabis and hemp companies, including cultivators, oil processors, manufacturers, testing laboratories, among others. In addition, XS provides a full range of consulting services including equipment selection and procurement, through its network of preferred vendor partnerships with original equipment manufacturers and equipment distributors. Further, XS also provides a full range of all on-site support services, including staff recruitment, process development, and product formulation. This powerful dynamic provides an end-to-end solution for customers which results in recurring revenues, strong profit margins, and a proven business model for XS stakeholders.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This press release contains “forward-looking information” and may also contain statements that may constitute “forward-looking statements”, collectively “forward-looking information”, within the meaning of applicable Canadian securities legislation. Such forward-looking information is not representative of historical facts or information or current condition, but instead represent the beliefs and expectations regarding future events about the business and the industry and markets in which Xtraction Services operates, as well as plans or objectives of management, many of which, by their nature, are inherently uncertain. Generally, such forward-looking information can be identified by the use of terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking information contained herein may include but is not limited to, any additional share purchases by the Archytas including size, price and timing thereof.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Accordingly, readers should not place undue reliance on forward-looking statements, which are qualified in their entirety by this cautionary statement. Xtraction Services does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

This press release does not constitute an offer to sell nor a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Not for distribution to U.S. newswire services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities laws.

Contacts

Xtraction Services
David Kivitz

Chief Executive Officer

Antony Radbod
Chief Marketing Officer

Tel: 1-407-900-4737 Ext. 5
Email: ir@xtractnow.com
www.xtractnow.com

The post Xtraction Services Announces Purchase of Shares in the Open Market by Archytas Ventures LLC appeared first on CannabisFN.

EXMceuticals obtains its research and development license for its TecLab facilities in Portugal

VANCOUVER, British Columbia, Oct. 23, 2019 (GLOBE NEWSWIRE) — EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company” or “EXM”), a cultivator and producer of high-grade cannabis is pleased to announce that it has obtained the licence for cannabis research and development from INFARMED, the Portuguese National Authority of Medicines and Health Products. This license allows the company to make a huge step forward in its European operations by being able to import, research and refine cannabinoids and cannabis by-products in Europe. EXM’s fully operational R&D laboratory in Portugal will now develop cannabis-based products and also operate as a pilot-scale refinery for the transformation of cannabis-based ingredients.

With its Portuguese license, EXMceuticals is making a leap forward with regards to its activities in the country and the European Union. The company will now convert its research work into real-life wellness products and pursuit for innovative solutions. In parallel, EXM is optimizing the refining processes using state of the art technology.

“We are very pleased to reach this important step for our activities in Europe. This will enable us to expand our work, as well as operate our existing R&D Lab and pilot CBD refinery to its full potential and capacity. Cannabis research will now proceed under the guidance of our senior scientists, with the clear goal of product innovation. Our scientific staff will also standardize and optimize extraction and refining protocols that will in time permit us to scale up our worldwide extraction and refining capacity very significantly,” said Jonathan Summers, chairman of EXMceuticals. He added: “The focus, time and diligence that INFARMED and the Portuguese authorities have devoted to our license application has been highly impressive. We look forward to collaborating with INFARMED and the entire medical community in Portugal to produce pharmaceutical grade cannabinoid ingredients. These ingredients will be reliable, safe and highly effective for the consumers and will have a relevant impact for research and industry.”

The license will also enable EXMceuticals to initiate new research projects under the Portugal 2020 program, a Framework Program between Portugal and the European Commission that brings together the five European Structural and Investment Funds. EXM anticipates this to be one of many upcoming advances regarding the company’s R&D activities.

The license allows EXMceuticals to go further with its strategic R&D partnership program with the addition of a leading UK university and additional European universities in the next few weeks. EXMceuticals already have in place collaboration agreements with Nova University Lisbon, Lusófona University as well as with a leading Portuguese cosmetics company, prominent Portuguese Food & Beverage companies, and GFR Pharma, a leading Canadian contract manufacturer. The company R&D activities are focused on advanced research and innovation, training and collaboration within the industry and with its strategic partners.

EXM has already began, in Portugal, the construction and fit out of an industrial-scale refining facility which will comply to European Union’s GMP Standards. We anticipate this new industrial-scale facility to be completed, operational and fully licensed before end of first quarter of 2020. This industrial-scale facility will import large quantities of cannabis and hemp crude oil from our farms in Africa, and then refine it on-site to our client’s demands. The new industrial-scale facility will allow EXMceuticals to export very large volume of highest purity refined cannabis products to European Union and worldwide.

As EXM moves from the current pilot-scale facility towards industrial-scale production and increases the number and scope of the R&D projects undertaken, the company anticipates creating more than 80 highly qualified technical & scientific research jobs in Portugal.

Loan Agreement

The Company announces that it has entered into a loan facility agreement with Jonathan Summers, Chairman of the Company, for up to $500,000. Amounts funded under the facility are unsecured, repayable in December 2020 and bear interest at 15% per annum.  The company issued bonus special warrants to the lender which entitle the lender to acquire bonus shares at a price of $1.35 per share for 20% of the principal amount actually funded under the loan facility.  The special warrants convert into shares only if the lender subscribes to a future Company financing in the amount equal to outstanding loan amount.  Proceeds from the Loan will be allocated to ongoing business initiatives and general working capital purposes.

The loan agreement also provides for the grant of performance-based warrants, entitling the lender to acquire between 15% and 60% of the principal amount funded under the loan facility in shares at a price of $1.35 per share.  The percentage will be determined based on the Company’s share price at the time the loan is repaid, with a sliding scale starting from $1.35 to above $6.00.

Pursuant to Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”) the Company advises that the loan agreement is a related party transaction under MI 61-101 and is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to section 5.5(a) and section 5.7(1)(a) of the instrument.

ON BEHALF OF THE BOARD OF DIRECTORS OF EXMCEUTICALS INC.

Michel Passebon, Chief Executive Officer and Director

For further information contact:
Investor Relations
Email: investors@exmceuticals.com

Media Enquiries:
Email: media@exmceuticals.com

Europe – Jane Glover:  +44 (0) 203 757 4990

North America – Mélanie Guillemette: +1 819 668 2734

FOR MORE UPDATES ON THE COMPANY

Follow us on Twitter: https://twitter.com/EXMceuticals
Follow us on LinkedIn: https://www.linkedin.com/company/exm-ceuticals-portugal/

ABOUT INFARMED

INFARMED the Portuguese Government agency responsible for the protection of Public Health.

INFARMED is accountable to the Health Ministry, it evaluates, authorises, regulates and controls medical, pharmaceutical as well as health and cosmetics products.

Infarmed performs at national and European levels its control and supervisory responsibilities on medicines and health products and is the Portuguese Reference Laboratory on the Quality Control of Medicines within the scope of the Network of Official Medicines Control Laboratories (OMCL).

ABOUT EXMCEUTICALS

EXM’s activities are focused on the sustainable cultivation of cannabis and hemp, and the production of high-grade ingredients for the pharmaceutical, therapeutical, nutraceutical and cosmetic industries.  The Company proposes to sell the produced ingredients to international markets.

EXM, through its subsidiary, Prime Ranchers Limited, is able to cultivate and process cannabis in Uganda at an industrial scale. The Uganda processing facilities are installed and will produce and export pharmaceutical, therapeutical, nutraceutical and cosmetic grade cannabis ingredients.

EXM owns a provisional license in Malawi enabling the cultivation of 50Ha of Cannabis and is in the process of obtaining a full license, in partnership with a large local agro producer. Please see previous press releases for more detailed information on EXM Malawi activities.

EXM, through its subsidiary and in-country partner, holds the rights to a cannabis license in the Kuba Kingdom, Mweka, Kasai Province, Democratic Republic of Congo, and the rights to a land concession for the cultivation of cannabis and hemp, and processing and export of high-grade cannabis extracted ingredients.

EXM has also submitted applications and undertaken negotiations with local governments and partners in Ethiopia, Zambia, Eswatini and Burundi, in order to obtain licences to permit the cultivation of cannabis and hemp, as well as the processing, transformation and export of psychotropic and non-psychotropic cannabinoid ingredients. In Ethiopia, EXM is in its final stage of negotiation with the government for an agro-industrial park, of 4,000 hectares (9,880 acres) encompassing a free trade zone.

Neither the CSE nor the FSE has approved nor disapproved the contents of this news release.  Neither the CSE, nor the FSE accepts responsibility for the adequacy or accuracy of this release.

Certain statements and information included in this press release that, to the extent they are not historical fact, constitute forward-looking information or statements (collectively, “forward-looking statements”) within the meaning of applicable securities legislation.  Forward-looking statements, including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements.  Such risks and uncertainties include, among others, the risk factors included in the Company’s Filing Statement dated as of January 28, 2019, which is available under the Company’s SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company.

The post EXMceuticals obtains its research and development license for its TecLab facilities in Portugal appeared first on CannabisFN.

MediPharm Labs Supports Industry Development With Loyalist College Alliance

BARRIE, Ontario, Oct. 23, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce its wholly-owned subsidiary, MediPharm Labs Inc. (“MediPharm Labs”), has entered into a four-year strategic alliance with Loyalist College of Applied Arts & Technology (“Loyalist”) for education, training, development and applied research projects in collaboration with its Cannabis Applied Science program, the first post-graduate certificate of its kind in Canada.

“MediPharm Labs is pleased to partner with the forward-thinking team at Loyalist to help shape the future of the cannabis industry through innovative research and by contributing to the development of the next generation of cannabis scientists and professionals,” says Pat McCutcheon, Chief Executive Officer of MediPharm Labs. “The possibilities for unique product development and further advancements in cannabis processing methodologies and technology are very exciting, made possible by uniting our respective skills and expertise through this unique private/public partnership.”

MediPharm Labs will donate a total of $100,000 in value of cannabis concentrates, full spectrum extract, specially formulated distillates and/or isolates over the four-year alliance, for applied research projects conducted in collaboration with students and researchers at Loyalist’s Applied Research Centre for Natural Products and Medical Cannabis – Technology Access Centre.  Utilizing green technologies, including supercritical CO2 extraction, research projects will focus on cannabis product development, inform process optimization, and address natural product quality, consistency and safety. Through annual field trips and work-integrated placements at MediPharm Lab’s advanced processing facility, students will learn about Good Manufacturing Practices (“GMP”) and industrial-scale supercritical CO2 extraction, short-path distillation and chromatography for high-quality cannabinoid-based derivatives.

“Loyalist College is very proud to partner with MediPharm Labs,” says Dr. Ann Marie Vaughan, Loyalist College President and CEO. “This alliance demonstrates our capacity to collaboratively support commercially relevant applied research while facilitating student learning experiences. With advanced equipment and analytics, our industry-leading labs support education and training of students and industry personnel, while enhancing innovation, productivity and global competitiveness of industry partners.”

Results of the applied research projects that develop from this partnership will be accessible to MediPharm Labs to incorporate into its platform built to GMP standards. This collaboration will strengthen MediPharm Labs’ capability to be a lead player in the marketplace.

About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-like cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices designed facility and ISO standard built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines having 300,000 kg of annual processing capacity to deliver pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale, white label and tolling platforms, they formulate, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, the Company also completed its first commercial export to Australia in June 2019 and is nearing completion of its Australian extraction facility expected in 2019 with 75,000 kg of annual processing capacity.

About Loyalist College
Loyalist is Ontario’s Destination College, empowering students, faculty, staff, and partners through experiential, industry cluster-based education, training and applied research programs. The College provides job-ready graduates for, and knowledge transfer to, industry and the community. Of 2017-18 Loyalist graduates, 88.5% percent were employed within six months after graduation. Located on more than 200 acres in the beautiful Bay of Quinte region, the College is perfectly positioned between Toronto, Ottawa and Montreal. Loyalist offers more than 70 full-time diploma, certificate and apprenticeship programs in biosciences, building sciences, business, community service, health and wellness, media studies, public safety, and skilled trades. Continuing education options are available through LoyalistFocus.com; including hundreds of online, distance and in-class courses; and through the College’s 100+ university transfer agreements. Loyalist is a key driver of social and economic health in eastern Ontario. It contributes 5.8 percent of the Gross Regional Product, representing $465 million annually to the regional economy – based on an October 2018 report by Emsi. For more information on Loyalist’s Belleville and Bancroft campuses and Port Hope satellite location, visit youregoingplaces.com.

Loyalist College’s Cannabis Applied Science Program
Loyalist College’s eight-month Cannabis Applied Science (CSGS) Ontario College post-graduate certificate program is the first of its kind in Canada. It allows students to build on their Ontario College diploma, degree or equivalent in the Sciences, Biology or a related discipline with in-depth skills to support cannabis product development, inform process optimization, and address natural product quality, consistency and safety. Cannabis Applied Science students learn in Loyalist’s Applied Research Centre for Natural Products and Medical Cannabis (ARC), a state-of-the-art Health Canada licensed facility, using advanced extraction technologies, and outside the classroom during a field placement with Licensed Producers where they apply their knowledge to real-world challenges. Students navigate cannabis regulations, investigate tissue culture, formulation and advanced product development while developing a range of lab techniques for the extraction and analysis of cannabis, which can provide them and their employers with a competitive advantage. The program, which was developed based on extensive consultation with Licensed Producers and industry experts across the sector, focuses on green technologies, including supercritical CO2 extraction, to support industry’s transition away from the use of petrochemical solvents. It prepares students for new career opportunities, ranging from roles such as cannabis quality assurance manager and lead processing technician to formulation chemist. Applications for the program are accepted through ontariocolleges.ca.

Loyalist College’s Applied Research Centre for Natural Products and Medical Cannabis
In June 2019, Loyalist College launched Canada’s first Technology Access Centre (TAC) for Natural Products and Cannabis. Loyalist College was the recipient of a $1,750,000 Natural Sciences and Engineering Research Council of Canada (NSERC) College and Community Innovation (CCI) Program grant over five years to launch the TAC. In addition, Loyalist received $1M through the Canada Foundation for Innovation’s (CFI) College-Industry Innovation Fund (CIIF) to add specialized equipment. As a TAC, Loyalist is building on the ARC’s 15 years of natural product extraction expertise and analysis-based applied research. In transitioning to a TAC, Loyalist’s ARC is significantly increasing the College’s capacity to lead applied research of commercially relevant natural products and cannabis, and to support innovation by enhancing industries’ access to sector-relevant expertise and technology. Loyalist offers companies across Canada a supportive, community-oriented platform from which to enhance their productivity, expand their reach and augment their competitiveness in the global market.

For further information, please contact:
Laura Lepore, Vice President, Investor Relations & Communications
Telephone: 705-719-7425 ext 216
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, product development and further advancements in cannabis processing methodologies and technology, completion of the Company’s Australian facility and timing thereof, and expected processing capacity of the Australian facility. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of the Company to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in the Company’s filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

Primary Logo

The post MediPharm Labs Supports Industry Development With Loyalist College Alliance appeared first on CannabisFN.

cbdMD, Inc. Announces Timing of Regular Monthly Dividend for November 2019 for 8.0% Series A Cumulative Convertible Preferred Stock

CHARLOTTE, N.C.

cbdMD, Inc. (NYSE American: YCBD), a nationally recognized consumer cannabidiol (CBD) brand, today announced the timing for the payment of its declared regular monthly dividend of $0.0667 per share of its 8.0% Series A Cumulative Convertible Preferred Stock (NYSE American: YCBD PR A) for November 2019. The dividend will be payable on November 15, 2019 to holders of record as of November 1, 2019. The dividend will be paid in cash. The November 2019 dividend is the first dividend declared by us on our 8% Series A Cumulative Convertible Preferred Stock following the issuance of these shares in a firm commitment underwritten public offering which closed on October 16, 2019.

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD and NYSE American: YCBD PR A) owns and operates the nationally recognized consumer cannabidiol (CBD) brand cdbMD, whose current products include CBD gummies, CBD tinctures, CBD topical, CBD bath bombs, CBD oils and CBD pet products. cbdMD, Inc. is a nationally recognized consumer cannabidiol (CBD) brand whose current products include CBD tinctures, CBD gummies, CBD topicals, CBD bath bombs, and CBD pet products. cbdMD is also the proud partner with the Big 3 Basketball League, Barstool Sports, Bellator MMA, (a subsidiary of Viacom: NASDAQ:VIA), LifeTime and Nitro Circus. To learn more about cbdMD, Inc. and our comprehensive line of over 100 SKU’s of U.S. produced, THC-free CBD products, please visit: www.cbdmd.com or follow cbdMD on Instagram and Facebook or visit one of the 3,000 retail outlets that carry cbdMD products.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. The information which appears on our website and our social media platforms is not part of this press release.

cbdMD, Inc.
Mark S. Elliott, Chief Financial Officer and Chief Operating Officer
(704) 445-3060
mark.elliott@cbdMD.com

The post cbdMD, Inc. Announces Timing of Regular Monthly Dividend for November 2019 for 8.0% Series A Cumulative Convertible Preferred Stock appeared first on CannabisFN.

FluroTech Announces September and Q3 2019 Revenue

CALGARY, Alberta, Oct. 23, 2019 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF), (“FluroTech” or the “Company”), a technology company focused on the analytical cannabis and hemp testing market, is pleased to announce five unit sales which generated revenue of $116,548 in September, the end of FluroTech’s third quarter of 2019. With the commercialization of the CompleTestTM, the Company continues to ramp up sales efforts through expansion of the sales team, ongoing negotiations with distributors in the United States, and the launch of a referral program with industry participants possessing demonstrated national and international reach.

“I’m pleased with the market acceptance and proof of concept of the CompleTestTM. We have a number of potential sales in the pipeline and expect quarterly growth in sales as numerous strategies are underway which are likely to expand the Company’s market reach and penetration,” stated Danny Dalla-Longa Chief Executive Officer. “New products which allow for further differentiation from competitors of the CompleTestTM are anticipated to be launched in Q4.  We are excited about the future potential of FluroTech.”

Currently, FluroTech’s sales and marketing team is validating the cadmium testing protocol designed by the scientific development team and are preparing for its introduction to the market. The cadmium test is the first of four heavy metal tests which will also include mercury, lead and arsenic.

About FluroTech (TSX-V: TEST) (OTCQB: FLURF)

FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech’s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples. Using the technology that was developed at the University of Calgary, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.

To learn more, visit www.FluroTech.com.

Contact Information

Danny Dalla-Longa
Chief Executive Officer
403.680.0644
danny@flurotech.com

FluroTech Ltd.
7 – 3535 Research Road NW
Calgary, AB T2L 2K8
info@flurotech.com

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the benefits to be realized from the Research License, the release of a low THCA testing protocol for hemp and the timing thereof, the release of a cadmium testing protocol and the timing thereof and the benefits of such additional product lines.

The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the need and demand for the CompleTestTM and biotracker technology in the cannabis and hemp industry and the potential uses of the biotracker technology, the market for a low THCA testing protocol for hemp and the market for cadmium testing, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to, adverse market conditions and regulatory and other risks associated with the cannabis and hemp industries in general, users of the Company’s the CompleTest™ failing to achieve the anticipated benefits of the product, competition from other developers of similar technology , failure to reach commercialization of the technology, failure to realize the anticipated benefits from the Research License, a lack of demand for low THCA and cadmium testing

The post FluroTech Announces September and Q3 2019 Revenue appeared first on CannabisFN.

FSD Pharma: Still Great Value Within The Market

In early 2019, the leadership at FSD Pharma Inc. (CSE: HUGE, OTCQB: FSDDD, Forum) realized that the nascent cannabis industry in Canada is heading into a supply gut and a major shortfall in sales.

The medical research and development Company terminated its joint venture agreement with Auxly Cannabis Group Inc. (TSX-V: XLY), which was a controversial move, but in hindsight, proved to be a seminal decision.

Intending to develop a portion of FSD Pharma’s cannabis cultivation facility, the Company had invested $7.5 million into construction by the time the agreement was terminated over contractual breaches.

Conventional wisdom in the cannabis industry has favoured growth over profitability. FSD decided to choose measured growth and control its expenses. Ending the Auxly relationship was not a popular decision at the time, but left unchecked, the joint venture would have only added to the market’s oversupply, along with compounding expenses for buildout and HR requirements, putting FSD into a very precarious financial situation.

This glut of supply (and a shortfall in sales), combined with packaging issues, distribution delays and regulatory challenges, led to a prudent decision by FSD’s leadership. In forecasting the industry challenges, the Company moved to protect its shareholder value by not investing precious resources into an expensive build out of the Cobourg, Ontario facility.

Even so, FSD still has tremendous production potential – nearly 4 million square feet of production space in one location — the worlds largest indoor facility.

Compared to the largest growers in Canada combined: Aurora Cannabis (TSX:ACB) , Aprhia Inc. (TSX:APH) and The Green Organic Dutchman (TSX:TGOD) can produce in excess of 1.5 million kg of cannabis a year at peak capacity, which is roughly 10 times current production.

Instead, FSD is looking deeper into its own resources. The Company will be the first in the cannabis industry to double-down its advance of R&D into synthetic cannabinoid compounds. Through FDA approved clinical trials, the goal will be to target the endocannibinoid system of the human body, with the grander objective to eventually commercialize cannabinoid-based prescription medications in United States and around the world. This would help alleviate pain and suffering of countless number of people, while targeting certain diseases of the central nervous system, some skin conditions and auto-immune musculoskeletal disorders.

To bring these plans of drug development into effect, FSD has taken a dual approach:

First, the Company launched its Biosciences Division earlier this year and acquired US-based Prismic Pharmaceuticals for $17.5 million. This is a platform company, with a world class expert in the field, Dr. Ed Brennan as the President of the Division. FSD also assembled the most robust and highly qualified Scientific Advisory Board under the leadership of Dr. Larry Kaiser, President & CEO of Temple Health system.

FSD Pharma has also embarked on a plan to list on a major US exchange and retained Paul Weiss law firm for legal assistance through the process.

FSD Pharma boasts strong fundamentals:

  1. No long term debt
  2. Non-cash assets of over $72 million
  3. The Company just raised $4.5 minion at a premium ($20.10 a share) with a major investment infusion by the CEO, Dr. Raza Bokhari, of $1.5 million USD, whose entire compensation is based on stock option plan
  4. The founders and insiders have also invested another $1 million
  5. The Company has an high profile independent Board of Directors that also includes a Former member of US Congress, Steve Buyer;
  6. Steve Buyer has personally invested $250,000 ($20.10 a share in the company), but has not signed any deals on the side. His voting record in Congress was against legalization of marijuana, but he believes in the promise the synthetic cannabinoid molecule holds in alleviating pain & suffering of countless through drug development based on FDA approved protocols

To increase visibility in the US capital markets and list on a major US exchange, on October 11th 2019, FSD announced the largest stock consolidation in the history of Canadian stock exchange. While this may not appear to be a popular decision at this time, much like the Company’s move to terminate its Auxly relationship,FSD’s leadership stands by this and views it to be just as seminal and appropriate.
FSDPharma.com

The post FSD Pharma: Still Great Value Within The Market appeared first on CannabisFN.

Planet 13 Launches Elysium, Sparkling Water Brand

  • Elysium is a THC-infused line of flavored sparkling water using all-natural flavors and zero added sugar

LAS VEGAS, Oct. 22, 2019 /CNW/ – Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNHF) (“Planet 13” or the “Company“), a leading vertically-integrated Nevada based cannabis company, announced today that it has launched a new beverage brand, Elysium, a refreshing THC-infused line of low-calorie flavored sparkling water.

Elysium (CNW Group/Planet 13 Holdings Inc.)

“Elysium marks our first step into the exciting THC beverage space. We’ve created and perfected a sparkling water beverage based on both customer demand and market trends. This low-calorie refreshing drink with zero added sugar was designed to be a fast-acting alternative without the guilt, the perfect micro-dosing beverage,” said Bob Groesbeck Co-CEO of Planet 13. “Our expanded production facility will enable us to increase production of our top selling TRENDI line and begin production of Elysium and our highly anticipated edibles lines Dreamland Chocolates and HaHa Gummies. Customers will be able to watch these brands being manufactured behind glass. Increased sales of inhouse brands will drive margin expansion and ultimately shareholder value.”

Elysium is a line of flavored sparkling beverages available in five flavours: Valencia Orange, Persian Lime, Eureka Lemon, Wild Berry, and Ruby Red Grapefruit. All flavors are low calorie, zero sugar using all-natural fruit flavourings and designed for an uplifting high.

About Planet 13
Planet 13 (www.planet13holdings.com) is a vertically integrated cannabis company based in Nevada, with award-winning cultivation, production and dispensary operations in Las Vegas – the entertainment capital of the world. Planet 13’s mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13’s shares trade on the Canadian Stock Exchange (CSE) under the symbol PLTH and OTCQX under the symbol PLNHF.

Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking-statements relate to, among other things, future expansion plans.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: final regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Nevada cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the State of Nevada; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through its subsidiary MMDC. Local state laws where MMDC operates permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form dated April 30, 2019 filed on its issuer profile on SEDAR at www.sedar.com.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

SOURCE Planet 13 Holdings Inc.

LodeRock Advisors Inc., Planet 13 Investor Relations, mark.kuindersma@loderockadvisors.com, (416) 519-2156 ext. 2230; Robert Groesbeck or Larry Scheffler, Co-Chief Executive Officers, ir@planet13lasvegas.comCopyright CNW Group 2019

The post Planet 13 Launches Elysium, Sparkling Water Brand appeared first on CannabisFN.

Planet 13 Launches Elysium, Sparkling Water Brand

  • Elysium is a THC-infused line of flavored sparkling water using all-natural flavors and zero added sugar

LAS VEGAS, Oct. 22, 2019 /CNW/ – Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNHF) (“Planet 13” or the “Company“), a leading vertically-integrated Nevada based cannabis company, announced today that it has launched a new beverage brand, Elysium, a refreshing THC-infused line of low-calorie flavored sparkling water.

Elysium (CNW Group/Planet 13 Holdings Inc.)

“Elysium marks our first step into the exciting THC beverage space. We’ve created and perfected a sparkling water beverage based on both customer demand and market trends. This low-calorie refreshing drink with zero added sugar was designed to be a fast-acting alternative without the guilt, the perfect micro-dosing beverage,” said Bob Groesbeck Co-CEO of Planet 13. “Our expanded production facility will enable us to increase production of our top selling TRENDI line and begin production of Elysium and our highly anticipated edibles lines Dreamland Chocolates and HaHa Gummies. Customers will be able to watch these brands being manufactured behind glass. Increased sales of inhouse brands will drive margin expansion and ultimately shareholder value.”

Elysium is a line of flavored sparkling beverages available in five flavours: Valencia Orange, Persian Lime, Eureka Lemon, Wild Berry, and Ruby Red Grapefruit. All flavors are low calorie, zero sugar using all-natural fruit flavourings and designed for an uplifting high.

About Planet 13
Planet 13 (www.planet13holdings.com) is a vertically integrated cannabis company based in Nevada, with award-winning cultivation, production and dispensary operations in Las Vegas – the entertainment capital of the world. Planet 13’s mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13’s shares trade on the Canadian Stock Exchange (CSE) under the symbol PLTH and OTCQX under the symbol PLNHF.

Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking-statements relate to, among other things, future expansion plans.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: final regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Nevada cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the State of Nevada; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through its subsidiary MMDC. Local state laws where MMDC operates permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form dated April 30, 2019 filed on its issuer profile on SEDAR at www.sedar.com.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

SOURCE Planet 13 Holdings Inc.

LodeRock Advisors Inc., Planet 13 Investor Relations, mark.kuindersma@loderockadvisors.com, (416) 519-2156 ext. 2230; Robert Groesbeck or Larry Scheffler, Co-Chief Executive Officers, ir@planet13lasvegas.comCopyright CNW Group 2019

The post Planet 13 Launches Elysium, Sparkling Water Brand appeared first on CannabisFN.

Indiva Announces Pre-Roll Partnership with the Supreme Cannabis Company, Inc.

LONDON, ON, Oct. 22, 2019 /CNW/ – Indiva Limited (the “Company” or “Indiva“) (TSXV: NDVA) (OTCQX: NDVAF) is pleased to announce it has signed a definitive agreement with The Supreme Cannabis Company, Inc. (“Supreme Cannabis”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) to manufacture and distribute pre-rolls for Supreme Cannabis’ portfolio of brands from Indiva’s facility in London, Ontario. The Supreme Cannabis portfolio includes recognized premium recreational and wellness brands like 7ACRES, Blissco and KKE.

Logo: Indiva Limited (CNW Group/Indiva Limited)

“This partnership truly represents the best of Canada’s cannabis industry. Together, Indiva and Supreme Cannabis will combine High End Cannabis™ with Indiva’s signature handcrafted pre-rolls,” Niel Marotta, Indiva’s President and Chief Executive Officer, said. “We take a lot of pride in each and every pre-roll that we send to market and are pleased that our partners in the industry recognize the value of exceptional quality. Our commitment to consistency is shared by Supreme Cannabis and we are thrilled to support their passion for craftsmanship and dedication to growing better and in this case, together.”

The agreement is for a one-year renewable term and is subject to minimum bi-weekly manufacturing volumes. The partnership is expected to initiate processing in late October. Indiva and Supreme Cannabis intend to work together to make product available across Canada.

Both INDIVA™ products and Supreme Cannabis’ suite of brands are available online and in stores where cannabis is sold. Click here to learn more about Indiva and Supreme Cannabis.

ABOUT INDIVA
Indiva’s global family of cannabis brands set the standard for quality and innovation. Indiva aims to bring its exceptional portfolio of products to Canadians and cannabis enthusiasts around the world as laws permit. Indiva’s production facility, based in London, Ontario, includes aeroponic, environmentally-conscious grow rooms and a nearly completed extraction and manufacturing space, which will be able to process 70 tonnes of biomass annually and produce safe, high-quality cannabis-infused edibles. In Canada, Indiva will produce and distribute Ruby® Cannabis Sugar, Sapphire™ Cannabis Salt and Ruby® Gems, as well as the award-winning Bhang® Chocolate, and other derivative products through licence agreements and joint ventures. Click here to connect with Indiva on social media and here to find more information on the Company and its products.

DISCLAIMER AND READER ADVISORY
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has in any way passed upon the merits of the Transaction and neither of the foregoing entities accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the Company’s future operations, future product offerings and entry into additional markets, changes to laws and regulations in Canada and internationally, and compliance with applicable regulations. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include the parties being able to obtain the necessary regulatory and other third parties’ approvals and licensing and other risks associated with regulated entities in the cannabis industry. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

SOURCE Indiva Limited

MEDIA CONTACT : Kate Abernathy, Vice President of Communications, Phone: 613-296-5764, Email: kabernathy@Indiva.com; INVESTOR CONTACT : Steve Low, Investor Relations, Phone: 647-620-5101, Email: slow@Indiva.comCopyright CNW Group 2019

The post Indiva Announces Pre-Roll Partnership with the Supreme Cannabis Company, Inc. appeared first on CannabisFN.

Cansortium Announces a Reorganization of Senior Management and its Board of Directors, Significant Cost Reductions and the Prioritization and Acceleration of Growth in the U.S. Markets, Particularly Florida

Miami, Florida–(Newsfile Corp. – October 22, 2019) – Cansortium Inc. (CSE: TIUM.U) (OTCQB: CNTMF) (“Cansortium” or the “Company”) and its Board of Directors (the “Board’) have implemented a series of important corporate initiatives aimed at driving sustainable, profitable growth in the Company’s core market of Florida by allocating the necessary capital to expand the number of dispensaries in the state to twenty by the end of 2019. These initiatives are also aimed at ensuring that the Company has the operational flexibility and necessary liquidity to expand on its cultivation and dispensary footprint in the highly attractive markets of Michigan, Texas and Pennsylvania. Consistent with this refocused growth strategy, the Company is evaluating strategic alternatives with respect to non-core assets in Canada, Puerto Rico and Colombia to allow management to focus its attention exclusively on its U.S. markets.

The Board has been reduced to four members, three of whom are independent directors with deep business and corporate governance expertise. Additionally, the Board has established a special committee (the “Special Committee”) comprised of its three independent directors, Neal Hochberg, David Abrams and John McKimm, that has engaged financial and legal advisors to assist in the execution of the Company’s strategic reorganization and growth initiatives. As previously announced, Jose Hidalgo, Cansortium’s Co-Founder and Chief Executive Officer, has resigned from the position of Chairman, which has been assumed by Mr. Hochberg. Mr. Hochberg will also act as Chair of the Special Committee.

Staff and Cost Reductions and Board of Directors Reorganization

Following a comprehensive review of Cansortium’s corporate structure and management positions, the Board has approved the implementation of cost saving initiatives resulting in more than $4.5 million of aggregate annualized savings. Cost savings were derived from reductions in the workforce, the elimination of senior management positions and reductions in executive management compensation. The Special Committee believes that these improvements to the Company’s cost structure will enable management to execute on the Company’s growth plan and generate sustainable profits by the end of 2019.

In connection with a streamlined growth strategy and staff realignment, the Company has accepted the voluntary resignations of Patrick Maloy as Chief Operating Officer and Director, and Jeffrey Reath as Executive Vice President Finance and Investor Relations and Director. Each will be retained as consultants and continue to assist the Company in achieving its 2019 business and revenue goals.

In addition, Co-Founder Henry Batievsky has been named Chief Production Officer to solely focus on matching production to consumer demand and driving sales growth. Marcos Pedreira, formerly Cansortium’s Head of Finance, will assume the role of Chief Financial Officer, leveraging his previous public company financial and reporting experience. Mr. Hidalgo, Mr. Batievsky and Mr. Pedreira will be responsible for executing the strategy that has been approved by the Board.

Acceleration of Florida Expansion

Cansortium is undergoing a period of rapid growth in its Florida operations with monthly average sales increasing in its dispensary network. The Company expects to be operating at full capacity in its cultivation facility in Tampa by the end of 2019, which management believes will provide sufficient flower and oil to meet demand as the Company expands its dispensary footprint in highly strategic locations. It is a top strategic priority of the Company to have all dispensaries permitted under the Company’s license operational as soon as practicable. The Company expects to open its seventeenth and eighteenth Florida dispensaries in Jacksonville and Kendall, respectively, by the middle of November 2019, with two additional dispensaries scheduled to open during Q4 2019 in Lakeland and Coral Gables. This will expand the Company’s footprint from the current sixteen operational dispensaries to twenty dispensaries across Florida prior to year-end 2019. The Company’s twenty-first location, in the heart of Miami Beach, is expected to open by early 2020. An additional six locations are in the permitting and zoning stages with plans to open in 2020.

Other Attractive U.S. Markets

As a vertically-integrated operator in Florida, Cansortium has developed strong proficiencies in each of cultivation, processing, retail, and distribution activities. This expertise positions Cansortium to drive significant value from its license and operations in Texas, where Cansortium is one of only three licensed cannabis companies and where regulations are becoming increasingly more favorable for driving revenue growth. The Company also operates a dispensary in Pennsylvania, with the option to open two additional dispensaries in the south central region. Cansortium is also active in Michigan, where its in-market partner is currently cultivating and has licenses pending for further cultivation, as well as for processing and retail operations.

Role of the Special Committee

Each of the Special Committee members has had distinguished careers, with proven track records in investments, financial services, operations and management. The Special Committee has retained INFOR Financial Inc., a leading independent Canadian investment bank, to provide financial advisory services, and McCarthy Tétrault LLP, a leading Canadian law firm, to provide legal advice.

“The Special Committee is highly engaged and committed to dedicating significant time and effort to ensure that Cansortium is in a position to fully capitalize on the considerable market opportunities in front of the Company,” states Chairman Neal Hochberg. “The cannabis sector continues to rapidly evolve, and I am confident that with the unwavering support and dedication of the Special Committee to the Company, Cansortium is well-positioned to deliver sustainable positive results to its shareholders and other key stakeholders. I would like to thank Patrick and Jeffrey for their vision and tireless efforts in helping to build Cansortium to its current level and I look forward to working closely with the Special Committee, other senior management and existing investors and advisors as we implement the strategies to drive profitable growth in Cansortium’s next phase of development.”

Special Committee Members

Neal Hochberg

Mr. Hochberg, the Chairman of Cansortium’s Board, is a Certified Public Accountant with a distinguished 40-year career in financial services. He was a Financial Advisory Partner at both PWC and KPMG and is a Senior Advisor to the leadership of FTI Consulting Forensic & Litigation Consulting segment, previously serving on FTI’s Executive Committee. Recently, he was also appointed by the Supreme Court of Florida to membership on the Florida Board of Bar Examiners. Previously, he served as the project delegate to the World Economic Forum Partnering Against Corruption Initiative for five years.

David Abrams

Mr. Abrams has more than 30 years experience in the financial services industry as a distressed debt, real estate and private equity investment professional, as well as an investment banker with significant restructuring and capital markets expertise. Currently, Mr. Abrams is the Chief Investment Officer for Harris Blitzer Sports & Entertainment, a global sports and entertainment business which owns the Philadelphia 76ers (NBA), the New Jersey Devils (NHL) and the Prudential Center in New Jersey. Previously, Mr. Abrams was the Founder and Managing Partner of the Apollo European Principal Finance Funds franchise at Apollo Global Management, which had approximately $10 billion of assets under management with a primary focus on acquiring distressed debt, real estate and non-performing loans. Mr. Abrams was also a Partner focusing on Global Corporate Credit and Distressed Debt at Cerberus Capital, a leading investment firm with more than $32 billion in assets under management. Mr. Abrams is currently a member of the Board of Directors of Norwegian Cruise Lines, the 3rd largest operator of cruise ships in the world with an equity market capitalization of $11.0 billion.

John McKimm

Mr. McKimm’s experience spans over 35 years serving as a director, officer and investor of many public and private companies, providing operations, investment banking, and corporate finance expertise. Mr. McKimm possesses in-depth knowledge in dealing with emerging and growing companies, having personally identified, negotiated, and executed more than 150 individual mergers, acquisitions, financing, reorganization and recapitalization transactions. Mr. McKimm has extensive expertise in corporate, financial and strategic reorganizations on a global basis, across multiple industry sectors and regulatory environments.

About Cansortium Inc.

Headquartered in Miami, Florida, and operating under the Fluent™ brand, Cansortium is focused on being the highest quality cannabis company in the State of Florida driven by unrelenting commitment to operational excellence from seed to sale. Cansortium has developed strong proficiencies in each of cultivation, processing, retail, and distribution activities, the result of successfully operating in the highly regulated cannabis industry. In addition to Florida, Cansortium is seeking to create significant shareholder value in the attractive markets of Texas, Michigan and Pennsylvania, where the Company has secured licenses and established operations.

Cansortium Inc.’s common shares and warrants trade on the CSE under the symbol “TIUM.U” and “TIUM.WT.U”, respectively, and on the OTCQB Venture Market under the symbol (OTCQB: CNTMF). Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.

Forward-Looking Information

Certain information in this news release, may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For information on Cansortium Inc., please visit www.cansortium.com

SOURCE Cansortium Inc.

For further information:
Neal Hochberg, Chairman
neal@getfluent.com; 646-752-5736

The post Cansortium Announces a Reorganization of Senior Management and its Board of Directors, Significant Cost Reductions and the Prioritization and Acceleration of Growth in the U.S. Markets, Particularly Florida appeared first on CannabisFN.

Cansortium Announces a Reorganization of Senior Management and its Board of Directors, Significant Cost Reductions and the Prioritization and Acceleration of Growth in the U.S. Markets, Particularly Florida

Miami, Florida–(Newsfile Corp. – October 22, 2019) – Cansortium Inc. (CSE: TIUM.U) (OTCQB: CNTMF) (“Cansortium” or the “Company”) and its Board of Directors (the “Board’) have implemented a series of important corporate initiatives aimed at driving sustainable, profitable growth in the Company’s core market of Florida by allocating the necessary capital to expand the number of dispensaries in the state to twenty by the end of 2019. These initiatives are also aimed at ensuring that the Company has the operational flexibility and necessary liquidity to expand on its cultivation and dispensary footprint in the highly attractive markets of Michigan, Texas and Pennsylvania. Consistent with this refocused growth strategy, the Company is evaluating strategic alternatives with respect to non-core assets in Canada, Puerto Rico and Colombia to allow management to focus its attention exclusively on its U.S. markets.

The Board has been reduced to four members, three of whom are independent directors with deep business and corporate governance expertise. Additionally, the Board has established a special committee (the “Special Committee”) comprised of its three independent directors, Neal Hochberg, David Abrams and John McKimm, that has engaged financial and legal advisors to assist in the execution of the Company’s strategic reorganization and growth initiatives. As previously announced, Jose Hidalgo, Cansortium’s Co-Founder and Chief Executive Officer, has resigned from the position of Chairman, which has been assumed by Mr. Hochberg. Mr. Hochberg will also act as Chair of the Special Committee.

Staff and Cost Reductions and Board of Directors Reorganization

Following a comprehensive review of Cansortium’s corporate structure and management positions, the Board has approved the implementation of cost saving initiatives resulting in more than $4.5 million of aggregate annualized savings. Cost savings were derived from reductions in the workforce, the elimination of senior management positions and reductions in executive management compensation. The Special Committee believes that these improvements to the Company’s cost structure will enable management to execute on the Company’s growth plan and generate sustainable profits by the end of 2019.

In connection with a streamlined growth strategy and staff realignment, the Company has accepted the voluntary resignations of Patrick Maloy as Chief Operating Officer and Director, and Jeffrey Reath as Executive Vice President Finance and Investor Relations and Director. Each will be retained as consultants and continue to assist the Company in achieving its 2019 business and revenue goals.

In addition, Co-Founder Henry Batievsky has been named Chief Production Officer to solely focus on matching production to consumer demand and driving sales growth. Marcos Pedreira, formerly Cansortium’s Head of Finance, will assume the role of Chief Financial Officer, leveraging his previous public company financial and reporting experience. Mr. Hidalgo, Mr. Batievsky and Mr. Pedreira will be responsible for executing the strategy that has been approved by the Board.

Acceleration of Florida Expansion

Cansortium is undergoing a period of rapid growth in its Florida operations with monthly average sales increasing in its dispensary network. The Company expects to be operating at full capacity in its cultivation facility in Tampa by the end of 2019, which management believes will provide sufficient flower and oil to meet demand as the Company expands its dispensary footprint in highly strategic locations. It is a top strategic priority of the Company to have all dispensaries permitted under the Company’s license operational as soon as practicable. The Company expects to open its seventeenth and eighteenth Florida dispensaries in Jacksonville and Kendall, respectively, by the middle of November 2019, with two additional dispensaries scheduled to open during Q4 2019 in Lakeland and Coral Gables. This will expand the Company’s footprint from the current sixteen operational dispensaries to twenty dispensaries across Florida prior to year-end 2019. The Company’s twenty-first location, in the heart of Miami Beach, is expected to open by early 2020. An additional six locations are in the permitting and zoning stages with plans to open in 2020.

Other Attractive U.S. Markets

As a vertically-integrated operator in Florida, Cansortium has developed strong proficiencies in each of cultivation, processing, retail, and distribution activities. This expertise positions Cansortium to drive significant value from its license and operations in Texas, where Cansortium is one of only three licensed cannabis companies and where regulations are becoming increasingly more favorable for driving revenue growth. The Company also operates a dispensary in Pennsylvania, with the option to open two additional dispensaries in the south central region. Cansortium is also active in Michigan, where its in-market partner is currently cultivating and has licenses pending for further cultivation, as well as for processing and retail operations.

Role of the Special Committee

Each of the Special Committee members has had distinguished careers, with proven track records in investments, financial services, operations and management. The Special Committee has retained INFOR Financial Inc., a leading independent Canadian investment bank, to provide financial advisory services, and McCarthy Tétrault LLP, a leading Canadian law firm, to provide legal advice.

“The Special Committee is highly engaged and committed to dedicating significant time and effort to ensure that Cansortium is in a position to fully capitalize on the considerable market opportunities in front of the Company,” states Chairman Neal Hochberg. “The cannabis sector continues to rapidly evolve, and I am confident that with the unwavering support and dedication of the Special Committee to the Company, Cansortium is well-positioned to deliver sustainable positive results to its shareholders and other key stakeholders. I would like to thank Patrick and Jeffrey for their vision and tireless efforts in helping to build Cansortium to its current level and I look forward to working closely with the Special Committee, other senior management and existing investors and advisors as we implement the strategies to drive profitable growth in Cansortium’s next phase of development.”

Special Committee Members

Neal Hochberg

Mr. Hochberg, the Chairman of Cansortium’s Board, is a Certified Public Accountant with a distinguished 40-year career in financial services. He was a Financial Advisory Partner at both PWC and KPMG and is a Senior Advisor to the leadership of FTI Consulting Forensic & Litigation Consulting segment, previously serving on FTI’s Executive Committee. Recently, he was also appointed by the Supreme Court of Florida to membership on the Florida Board of Bar Examiners. Previously, he served as the project delegate to the World Economic Forum Partnering Against Corruption Initiative for five years.

David Abrams

Mr. Abrams has more than 30 years experience in the financial services industry as a distressed debt, real estate and private equity investment professional, as well as an investment banker with significant restructuring and capital markets expertise. Currently, Mr. Abrams is the Chief Investment Officer for Harris Blitzer Sports & Entertainment, a global sports and entertainment business which owns the Philadelphia 76ers (NBA), the New Jersey Devils (NHL) and the Prudential Center in New Jersey. Previously, Mr. Abrams was the Founder and Managing Partner of the Apollo European Principal Finance Funds franchise at Apollo Global Management, which had approximately $10 billion of assets under management with a primary focus on acquiring distressed debt, real estate and non-performing loans. Mr. Abrams was also a Partner focusing on Global Corporate Credit and Distressed Debt at Cerberus Capital, a leading investment firm with more than $32 billion in assets under management. Mr. Abrams is currently a member of the Board of Directors of Norwegian Cruise Lines, the 3rd largest operator of cruise ships in the world with an equity market capitalization of $11.0 billion.

John McKimm

Mr. McKimm’s experience spans over 35 years serving as a director, officer and investor of many public and private companies, providing operations, investment banking, and corporate finance expertise. Mr. McKimm possesses in-depth knowledge in dealing with emerging and growing companies, having personally identified, negotiated, and executed more than 150 individual mergers, acquisitions, financing, reorganization and recapitalization transactions. Mr. McKimm has extensive expertise in corporate, financial and strategic reorganizations on a global basis, across multiple industry sectors and regulatory environments.

About Cansortium Inc.

Headquartered in Miami, Florida, and operating under the Fluent™ brand, Cansortium is focused on being the highest quality cannabis company in the State of Florida driven by unrelenting commitment to operational excellence from seed to sale. Cansortium has developed strong proficiencies in each of cultivation, processing, retail, and distribution activities, the result of successfully operating in the highly regulated cannabis industry. In addition to Florida, Cansortium is seeking to create significant shareholder value in the attractive markets of Texas, Michigan and Pennsylvania, where the Company has secured licenses and established operations.

Cansortium Inc.’s common shares and warrants trade on the CSE under the symbol “TIUM.U” and “TIUM.WT.U”, respectively, and on the OTCQB Venture Market under the symbol (OTCQB: CNTMF). Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.

Forward-Looking Information

Certain information in this news release, may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For information on Cansortium Inc., please visit www.cansortium.com

SOURCE Cansortium Inc.

For further information:
Neal Hochberg, Chairman
neal@getfluent.com; 646-752-5736

The post Cansortium Announces a Reorganization of Senior Management and its Board of Directors, Significant Cost Reductions and the Prioritization and Acceleration of Growth in the U.S. Markets, Particularly Florida appeared first on CannabisFN.

Cansortium Announces a Reorganization of Senior Management and its Board of Directors, Significant Cost Reductions and the Prioritization and Acceleration of Growth in the U.S. Markets, Particularly Florida

Miami, Florida–(Newsfile Corp. – October 22, 2019) – Cansortium Inc. (CSE: TIUM.U) (OTCQB: CNTMF) (“Cansortium” or the “Company”) and its Board of Directors (the “Board’) have implemented a series of important corporate initiatives aimed at driving sustainable, profitable growth in the Company’s core market of Florida by allocating the necessary capital to expand the number of dispensaries in the state to twenty by the end of 2019. These initiatives are also aimed at ensuring that the Company has the operational flexibility and necessary liquidity to expand on its cultivation and dispensary footprint in the highly attractive markets of Michigan, Texas and Pennsylvania. Consistent with this refocused growth strategy, the Company is evaluating strategic alternatives with respect to non-core assets in Canada, Puerto Rico and Colombia to allow management to focus its attention exclusively on its U.S. markets.

The Board has been reduced to four members, three of whom are independent directors with deep business and corporate governance expertise. Additionally, the Board has established a special committee (the “Special Committee”) comprised of its three independent directors, Neal Hochberg, David Abrams and John McKimm, that has engaged financial and legal advisors to assist in the execution of the Company’s strategic reorganization and growth initiatives. As previously announced, Jose Hidalgo, Cansortium’s Co-Founder and Chief Executive Officer, has resigned from the position of Chairman, which has been assumed by Mr. Hochberg. Mr. Hochberg will also act as Chair of the Special Committee.

Staff and Cost Reductions and Board of Directors Reorganization

Following a comprehensive review of Cansortium’s corporate structure and management positions, the Board has approved the implementation of cost saving initiatives resulting in more than $4.5 million of aggregate annualized savings. Cost savings were derived from reductions in the workforce, the elimination of senior management positions and reductions in executive management compensation. The Special Committee believes that these improvements to the Company’s cost structure will enable management to execute on the Company’s growth plan and generate sustainable profits by the end of 2019.

In connection with a streamlined growth strategy and staff realignment, the Company has accepted the voluntary resignations of Patrick Maloy as Chief Operating Officer and Director, and Jeffrey Reath as Executive Vice President Finance and Investor Relations and Director. Each will be retained as consultants and continue to assist the Company in achieving its 2019 business and revenue goals.

In addition, Co-Founder Henry Batievsky has been named Chief Production Officer to solely focus on matching production to consumer demand and driving sales growth. Marcos Pedreira, formerly Cansortium’s Head of Finance, will assume the role of Chief Financial Officer, leveraging his previous public company financial and reporting experience. Mr. Hidalgo, Mr. Batievsky and Mr. Pedreira will be responsible for executing the strategy that has been approved by the Board.

Acceleration of Florida Expansion

Cansortium is undergoing a period of rapid growth in its Florida operations with monthly average sales increasing in its dispensary network. The Company expects to be operating at full capacity in its cultivation facility in Tampa by the end of 2019, which management believes will provide sufficient flower and oil to meet demand as the Company expands its dispensary footprint in highly strategic locations. It is a top strategic priority of the Company to have all dispensaries permitted under the Company’s license operational as soon as practicable. The Company expects to open its seventeenth and eighteenth Florida dispensaries in Jacksonville and Kendall, respectively, by the middle of November 2019, with two additional dispensaries scheduled to open during Q4 2019 in Lakeland and Coral Gables. This will expand the Company’s footprint from the current sixteen operational dispensaries to twenty dispensaries across Florida prior to year-end 2019. The Company’s twenty-first location, in the heart of Miami Beach, is expected to open by early 2020. An additional six locations are in the permitting and zoning stages with plans to open in 2020.

Other Attractive U.S. Markets

As a vertically-integrated operator in Florida, Cansortium has developed strong proficiencies in each of cultivation, processing, retail, and distribution activities. This expertise positions Cansortium to drive significant value from its license and operations in Texas, where Cansortium is one of only three licensed cannabis companies and where regulations are becoming increasingly more favorable for driving revenue growth. The Company also operates a dispensary in Pennsylvania, with the option to open two additional dispensaries in the south central region. Cansortium is also active in Michigan, where its in-market partner is currently cultivating and has licenses pending for further cultivation, as well as for processing and retail operations.

Role of the Special Committee

Each of the Special Committee members has had distinguished careers, with proven track records in investments, financial services, operations and management. The Special Committee has retained INFOR Financial Inc., a leading independent Canadian investment bank, to provide financial advisory services, and McCarthy Tétrault LLP, a leading Canadian law firm, to provide legal advice.

“The Special Committee is highly engaged and committed to dedicating significant time and effort to ensure that Cansortium is in a position to fully capitalize on the considerable market opportunities in front of the Company,” states Chairman Neal Hochberg. “The cannabis sector continues to rapidly evolve, and I am confident that with the unwavering support and dedication of the Special Committee to the Company, Cansortium is well-positioned to deliver sustainable positive results to its shareholders and other key stakeholders. I would like to thank Patrick and Jeffrey for their vision and tireless efforts in helping to build Cansortium to its current level and I look forward to working closely with the Special Committee, other senior management and existing investors and advisors as we implement the strategies to drive profitable growth in Cansortium’s next phase of development.”

Special Committee Members

Neal Hochberg

Mr. Hochberg, the Chairman of Cansortium’s Board, is a Certified Public Accountant with a distinguished 40-year career in financial services. He was a Financial Advisory Partner at both PWC and KPMG and is a Senior Advisor to the leadership of FTI Consulting Forensic & Litigation Consulting segment, previously serving on FTI’s Executive Committee. Recently, he was also appointed by the Supreme Court of Florida to membership on the Florida Board of Bar Examiners. Previously, he served as the project delegate to the World Economic Forum Partnering Against Corruption Initiative for five years.

David Abrams

Mr. Abrams has more than 30 years experience in the financial services industry as a distressed debt, real estate and private equity investment professional, as well as an investment banker with significant restructuring and capital markets expertise. Currently, Mr. Abrams is the Chief Investment Officer for Harris Blitzer Sports & Entertainment, a global sports and entertainment business which owns the Philadelphia 76ers (NBA), the New Jersey Devils (NHL) and the Prudential Center in New Jersey. Previously, Mr. Abrams was the Founder and Managing Partner of the Apollo European Principal Finance Funds franchise at Apollo Global Management, which had approximately $10 billion of assets under management with a primary focus on acquiring distressed debt, real estate and non-performing loans. Mr. Abrams was also a Partner focusing on Global Corporate Credit and Distressed Debt at Cerberus Capital, a leading investment firm with more than $32 billion in assets under management. Mr. Abrams is currently a member of the Board of Directors of Norwegian Cruise Lines, the 3rd largest operator of cruise ships in the world with an equity market capitalization of $11.0 billion.

John McKimm

Mr. McKimm’s experience spans over 35 years serving as a director, officer and investor of many public and private companies, providing operations, investment banking, and corporate finance expertise. Mr. McKimm possesses in-depth knowledge in dealing with emerging and growing companies, having personally identified, negotiated, and executed more than 150 individual mergers, acquisitions, financing, reorganization and recapitalization transactions. Mr. McKimm has extensive expertise in corporate, financial and strategic reorganizations on a global basis, across multiple industry sectors and regulatory environments.

About Cansortium Inc.

Headquartered in Miami, Florida, and operating under the Fluent™ brand, Cansortium is focused on being the highest quality cannabis company in the State of Florida driven by unrelenting commitment to operational excellence from seed to sale. Cansortium has developed strong proficiencies in each of cultivation, processing, retail, and distribution activities, the result of successfully operating in the highly regulated cannabis industry. In addition to Florida, Cansortium is seeking to create significant shareholder value in the attractive markets of Texas, Michigan and Pennsylvania, where the Company has secured licenses and established operations.

Cansortium Inc.’s common shares and warrants trade on the CSE under the symbol “TIUM.U” and “TIUM.WT.U”, respectively, and on the OTCQB Venture Market under the symbol (OTCQB: CNTMF). Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.

Forward-Looking Information

Certain information in this news release, may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For information on Cansortium Inc., please visit www.cansortium.com

SOURCE Cansortium Inc.

For further information:
Neal Hochberg, Chairman
neal@getfluent.com; 646-752-5736

The post Cansortium Announces a Reorganization of Senior Management and its Board of Directors, Significant Cost Reductions and the Prioritization and Acceleration of Growth in the U.S. Markets, Particularly Florida appeared first on CannabisFN.

Luxury Cannabis: Green Is the New Black

Look around. The world is going through a transformation that you’ll never see again with marijuana becoming mainstream. A decade ago, legal recreational cannabis was nearly a laughable idea and medical marijuana was a mostly overlooked small market. What a change seven years can make.

Now, the majority of Americans have legal access to marijuana in one form or another and the passage of the 2018 Farm Bill made hemp (a non-psychoactive cannabis sativa plant) legal nationwide.

Click here to receive an investor deck and corporate updates

Perhaps one of the most glaring changes is the negative stigma long-attached to marijuana disappearing. Consumers are becoming increasingly aware of the positive benefits of cannabis and that there is a tremendous difference between CBD (cannabidiol) and THC (tetrahydrocannabinol), the two most well-known compounds found in cannabis.

Specific consumer groups embracing cannabis is well demonstrated by a 2017 Marist/Yahoo News poll that showed women, baby boomers and people making over $50,000 annually expect to increase their usage of cannabis as it becomes legal more than other demographics.

Marketing is spearheading consumer education and shepherding a burgeoning luxury cannabis segment. To accelerate the trend, companies can target older demographics and affluent women ranging from minivan-driving soccer moms to helicopter parents in the same way that other luxury brands like Tapestry (NYSE: TPR) and Chanel might.

In fact, cannabis is becoming vogue and companies like The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF) (Frankfurt: YG3) are taking leadership positions with multiple luxury brands and a catalogue of over 200 cannabis beverage, edible, wellness and beauty formulas.

The Advertising Factor

Historically, when it came to any sort of cannabis-related advertising, there was pretty much one player: High Times magazine. Good or bad, High Times has generally been associated with the “stoner” stigma; not exactly the target market for luxury brands.

Thanks to innovators like Yield Growth, a market transformation is happening. Consumer goods companies have formulated premium products specifically for men and women and wrapped them in appealing high-end packaging. Digital ads for CBD products are found on billboards in major cities, including NYC’s Times Square. For Yield Growth, their products have been prominently featured on financial portals like Forbes, as well as leading lifestyle and fashion magazines showcasing their products.

Click here to receive an investor deck and corporate updates

For example, Yield Growth’s Urban Juve Anti-aging Serum with Hemp Oil has received acclaim on both sides of the Atlantic Ocean. Earlier this year, Elle Canada and Zoomer which, together, have about 3 million readers combined, sang the praises of the product.

Subsequently, the company took advantage of an invitation to showcase the all-natural hemp skin care line in the September edition of British Vogue. Urban Juve’s Anti-aging Serum with Hemp Oil was included in the print showcase entitled ‘Vogue’s Beauty Highlights’, which has been designed with the intention of promoting a range of hand-selected, premium beauty brands that may yet be undiscovered by British Vogue’s 1.1 million readers and industry insiders.

Additionally, the Urban Juve products were featured digitally on Vogue Retail, a part of Vogue.co.uk., which has 3 million website users.

That publicity was followed this month by the anti-aging serum being featured in the November issue of Vanity Fair UK, which just hit newsstands. The feature in Vanity Fair UK includes Urban Juve in its beauty showcase called “The Vanity Box,” showcasing a range of hand-picked luxury beauty products all perfectly suited to its affluent readers.

Girl Power

It’s interesting to note that Duchess of Sussex Meghan Markle guest edited the September edition of British Vogue, taking the opportunity to highlight women who are “forces for change.”

The women that run Yield Growth embody the Duchess’s spotlighted theme. It starts at the top with Co-Founder, President and CEO Penny White, a serial entrepreneur with an affinity for upstarts and highly-relevant experience of over twenty years building successful companies. Penny proves that business building is a bit agnostic to some extent, as she has been involved with over 100 companies spanning a broad spectrum of industries, including online music, international film distribution, blockchain technology, pharmaceuticals, law and more.

Amy Frankel, VP Licensing and General Counsel at BOSS, has nearly two decades of experience in providing legal advice to, and negotiating deals for, consumer product companies. Amongst her other positions, Ms. Frankel was co-general counsel of Aritzia LP (TSX: ATZ) and Associate General Counsel of shoe giant Skechers USA (NYSE: SKX). During her time at these companies, she was instrumental in negotiating inbound and outbound licensing deals and developing and managing robust intellectual property franchises, skills that are invaluable for the rapidly developing global brands of Yield Growth.

Tamara Melck, was recently appointed as Chief Operating Officer of Yield Growth.  Tamara has proven expertise in scaling operations. Among her career achievements, she was instrumental in the growth of Canadian fashion retailer Aritzia as its Vice President, Corporate Operations and Executive Vice President, People & Culture. When she joined in 2001, Aritzia had 10 stores and 30 head office employees, and Melck built several of the corporate backend functions from scratch, helping Aritzia to scale its operations and achieve $743M in annual revenue and to reach a market capitalization of over $1 billion when she left in 2017. Melck was a member and former chair of the Executive Committee of Aritzia, and she directly led and oversaw numerous departmental and cross-functional projects of all sizes to build the necessary infrastructure to enable growth.

Click here to receive an investor deck and corporate updates

The most recent addition to the Yield Growth executive team includes another Aritzia alum, Karla Cheon.  Former Director, e-Commerce and Online Experience at the leading fashion retailer, Cheon has been appointed Yield Growth’s new Vice President of Marketing.  Drawing from her nearly 15-year tenure at Aritzia where Ms. Cheon played a key role in numerous strategic growth initiatives, including Aritzia’s expansion into the USA (2007) and Quebec (2013), its eCommerce launch (2012), and its Initial Public Offering (2016), Karla expects leverage her e-Commerce and digital marketing expertise, two areas of critical importance to the success of any brand and key priorities for Yield Growth.

In addition to the aforementioned companies, Yield Growth management has experience with global brands like MAC Cosmetics (now owned by Estee Lauder (NYSE: EL) Johnson & Johnson (NYSE: JNJ), Procter & Gamble (NYSE: PG) and Best Buy, (NYSE: BBY).

The Key Takeaway

Cannabis has come a long way from buying a dime bag in some shaded alley. It is making its way mainstream and blossoming into an industry that Jefferies says broadly could become a $166 billion global market in the next decade, inclusive of a cannabis beauty market surging to $25 billion. To that end, skilled leaders recognize the massive opportunity and are aggressively aligning to grow new brands in the burgeoning market. The Yield Growth team has a knack for getting out in front of trends, which is exactly what they are doing with luxury cannabis as the next status symbol consumers don’t mind paying up for.

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

 

 

 

 

 

The post Luxury Cannabis: Green Is the New Black appeared first on CannabisFN.

Yield Growth Appoints Former Aritzia Director, E-commerce and Online Experience, Karla Cheon, as VP, Marketing

Vancouver, British Columbia–(Newsfile Corp. – October 22, 2019) – The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) is pleased to announce that seasoned marketing professional Karla Cheon has been appointed as Vice President, Marketing of Yield Growth, effective October 21, 2019.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/48977_PR-LI_Karlaresized.jpg

Yield Growth Appoints Vice President of Marketing, Karla Cheon.

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6377/48977_PR-LI_Karla.jpg

Cheon has a proven track record as a marketer for successful, growing brands. As a testament to her unique combination of marketing insight, brand-building talent and business acumen, she was selected to lead or partner on the marketing aspects of key strategic growth initiatives at Aritzia during her nearly 15-year tenure at the leading fashion retailer: Aritzia’s expansion into the USA (2007) and Quebec (2013), its eCommerce launch (2012), and its Initial Public Offering (2016). Aritzia is a vertically integrated, innovative design house of exclusive fashion brands. It reported net revenue of $874 million in Fiscal 2019.

In particular, Cheon has deep expertise in eCommerce and digital marketing, two areas of critical importance to the success of any brand. As Marketing Director, Interactive, she developed the content and traffic generation strategy for aritzia.com. Later, as Director, eCommerce Marketing and Online Experience, she was part of the team that built Aritzia’s first eCommerce website and was responsible for creating its award-winning online experience. As part of the IPO team, she also created Aritzia’s first-ever investors website.

“As Yield Growth prepares to launch new brands and expand its existing brands to new markets, Cheon’s marketing prowess will be invaluable,” says Penny White, CEO of Yield Growth.

Cheon holds a Bachelor of Arts degree with a focus on Communication, Culture and Information Technology from Queen’s University. She is eager to apply her marketing know-how in this burgeoning industry.

“As regulations around cannabis-based products come into alignment, there is a tremendous opportunity for brands who can meet both the needs of an increasingly savvy consumer who seeks high-quality, natural products, as well as demonstrate a commitment to acting responsibly,” says Cheon. “Yield’s portfolio is poised to take advantage of this, and I am tremendously excited to be part of shaping these brands.”

About The Yield Growth Corp.

The Yield Growth Corp. is building and operating hemp, cannabis and edible mushroom assets in what the Global Wellness Institute reports is a $4.2 trillion-dollar global wellness market. It owns the cannabis wellness brands Urban Juve, Wright & Well and Jack n Jane. The Yield Growth management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, M·A·C Cosmetics, Skechers, Best Buy and Aritzia. Its all natural hemp skin care brand, Urban Juve, has signed distribution agreements in Canada, Columbia, Brazil, Greece and Cypress and through its distributor network has access to over 8,000 retail locations. Urban Juve has been featured in UK Vogue, Vanity Fair UK and Elle Canada and has an alliance with leading online beauty community, ipsy. Yield Growth’s Wright & Well brands are launching a THC/CBD line of topical products in Oregon and a CBD from hemp topicals line in California this fall. Jack n Jane is launching cannabis products in Canada in 2019. Yield Growth is launching a line of edible mushroom wellness products in 2020.

Through its subsidiaries, Yield Growth has over 200 proprietary beauty, wellness, edibles and beverage formulas for commercialization. It had filed 12 patents to protect its extraction method and formulas. Yield Growth is in revenue through multiple streams including licensing, services and product sales.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram. Visit www.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.

Investor Relations Contacts:

Penny White, President & CEO

Kristina Pillon, Investor Relations

invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677

1-833-515-BOSS 1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, intellectual property protection, and sale of, and demand for, Urban Juve, Wright & Well, UJ Beverages, Jack n Jane and Flourish Mushroom products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48977

Source: Newsfile Corp. (October 22, 2019 – 2:04 AM EDT)

News by QuoteMedia

The post Yield Growth Appoints Former Aritzia Director, E-commerce and Online Experience, Karla Cheon, as VP, Marketing appeared first on CannabisFN.

Benzinga Cannabis Capital Conference Connecting Cannabis Investors & Executives in Chicago

The Benzinga Cannabis Capital Conference will take place at Chicago’s Palmer House on October 22 and 23, 2019. Cannabis investors will have a chance to come face-to-face with cannabis companies to hear about their advancements in the rapidly growing industry, while cannabis executives will have an opportunity to grow their business and attract investors with lightning round presentations and one-on-one meetings.

The conference will feature speakers including:

 

CFN Media Interviewing Mark Krytiuk, President of Nabis Holdings at the Toronto Benzinga Capital Conference 2019

 

CFN Media will provide full coverage of the conference via exclusive interviews with thought leaders and pioneering companies. If you’re company is interested in an interview, please contact Frank Lane at flane@cannabisfn.com or (800) 517-5820 to schedule a time. The coverage will be published on the CFN Media Video Library over the coming weeks.

About the Benzinga Cannabis Capital Conference

The Benzinga Cannabis Capital Conference is the premier gathering of cannabis entrepreneurs and investors in North America. No other conference offers the level of access and seamlessness of interaction between entrepreneurs building future billion-dollar cannabis enterprises and the investors whose capital will make that happen. 

Individuals or companies interested in attending the conference can buy tickets online at:

https://benzingacannabisconference.com/chicago/ 

About CFN Media

See other upcoming conferences on CannabisFN.com’s conference calendar:

https://www.cannabisfn.com/event-calendar/

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

For Visitors and Viewers 

CFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.

For Cannabis Businesses & Companies 

CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.

Our powerful digital media and distribution platform conveys a company’s message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.

Since 2013, CFN Media has enabled the world’s preeminent cannabis companies to thrive in the capital and public markets.

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

The post Benzinga Cannabis Capital Conference Connecting Cannabis Investors & Executives in Chicago appeared first on CannabisFN.

DNA Genetics’ CEO Charles Phillips to Speak at Benzinga Cannabis Capital Conference – Chicago

LOS ANGELES, Oct. 21, 2019 (GLOBE NEWSWIRE) — OG DNA Genetics (“DNA” or the “Company”), a globally recognized leading cannabis brand, announced that Charles Phillips, Chief Executive Officer, will be a guest speaker at this year’s Benzinga Cannabis Capital Conference held in Chicago at the Palmer House Hotel from October 22 – 23, 2019.

The Benzinga Cannabis Capital Conference is the premier gathering of cannabis entrepreneurs and investors in North America. No other conference offers the level of access and seamlessness of interaction between entrepreneurs building future billion-dollar cannabis enterprises and the investors whose capital will make that happen. Mr. Phillips’ will discuss how DNA Genetics’ brand awareness and award-winning cannabis strains ensure high-yield production, pharmacological efficacy and heightened consumer interest, making partnership and investment with DNA Genetics extremely valuable. Mr. Phillips presentation will take place on October 23rd at 10:30 a.m. CST.

After spending over a decade building their brand in the European marketplace, DNA established themselves as one of the most respected and well regarded cannabis brands in the world with licensing deals across the globe. For more than 15 years, DNA’s strains have won over 200 awards in all categories at cannabis events around the world, making DNA the global standard in breeding and growing.

Mr. Phillips joins DNA at a pivotal time in the company’s history as they position the legacy brand for public offering. Mr. Phillips began his career as an Associate at The Boston Consulting Group, receiving his bachelor’s degree in Government from Harvard University, and his Master of Business Administration from Stanford Graduate School of Business. He ran business development from 2017-18 at Harborside Health, a major cannabis retailer in Oakland, before joining DNA Genetics. Along with Mr. Phillips contributions to the growth of the DNA brand, he helped to successfully close the first two equity financings in the history of the company, bringing in an aggregate of US$35 million from a strong group of institutional and strategic investors.

About OG DNA Genetics Inc.

DNA was rooted in Los Angeles and founded in Amsterdam in 2004 by Don Morris and Aaron Yarkoni.  Over the last decade, the Company has built and curated a seasoned genetic library and developed proven standard operating procedures for genetic selection, breeding, and cultivation. In a world that is increasingly opening up to commercial cannabis activity, DNA is positioned to become the first, truly geographically-diversified company with multiple partnerships with top-licensed producers and brands that have built their companies and global presence utilizing the “Powered by DNA” model. For more information, please visit www.dnagenetics.com.

For further information, please contact Rezwan Khan, Vice President, Global Corporate Development at Rezwan@dnagenetics.com

The post DNA Genetics’ CEO Charles Phillips to Speak at Benzinga Cannabis Capital Conference – Chicago appeared first on CannabisFN.

High Tide Exceeds $797,000 in Systemwide Retail Cannabis Store Sales for the 3-Day Period Celebrating the First Anniversary of Legalization

CALGARY, Oct. 21, 2019 /CNW/ – High Tide Inc. (“High Tide” or the “Company”) (CSE:HITI) (OTCQB:HITIF) (Frankfurt:2LY), an Alberta-based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced over $797,000 in systemwide gross sales from the 26 branded Canna Cabana and KushBar retail cannabis stores from Thursday, October 17th – the first anniversary of the legalization of recreational cannabis for adult use across Canada (the “Anniversary of Legalization”) – through Saturday, October 19, 2019. Similar to its yearly reporting of retail sales related to April 20th, also known as ‘4/20’ in cannabis culture, the Company expects to announce the results associated with the annual Anniversary of Legalization going forward.

High Tide deployed various in-store promotions on cannabis products and accessories across its large retail network to acknowledge the significant milestone. “Much like on 4/20 every year, the strong data shows that customers were excited to mark the occasion with a special trip to or a larger-than-average purchase from their favourite Canna Cabana and KushBar store,” said Raj Grover, President and Chief Executive Officer of High Tide. “Canadian cannabis consumers were clearly happy to celebrate the first Anniversary of Legalization. The day was also the start of ‘Cannabis 2.0’ when cannabis edibles and concentrate products became legal, with those products expected to hit store shelves in early January,” added Mr. Grover. The Company opened its first retail cannabis store in late October of 2018 and then steadily established 25 more locations in three provinces over the next 11 months.

By mid-November, High Tide will have 30 branded retail cannabis locations across Canada barring any changes to the current rate of licensing by AGLC. The development permits for the remaining Canna Cabana and KushBar stores needed to achieve the AGLC’s maximum of 42 are secured and in-hand, with each location currently under various stages of development and construction. Outside of Alberta, High Tide currently has a Canna Cabana retail cannabis store in Swift Current, Saskatchewan, along with 3 branded locations in Hamilton, Sudbury and Toronto, Ontario.

About High Tide Inc.

High Tide is an Alberta-based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products. It is a vertically-integrated company in the Canadian cannabis market, with portfolio subsidiaries including RGR Canada Inc., Famous Brandz Inc., Kush West Distribution Inc., Smoker’s Corner Ltd., Grasscity.com, Canna Cabana Inc. and the majority of KushBar Inc. High Tide’s strategy as a parent company is to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value. Key industry investors in High Tide include Aphria Inc. (TSX: APHA) (NYSE: APHA) and Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB).

Representing the core of High Tide’s business, RGR Canada Inc. is a high-quality and innovative designer, manufacturer and distributor of cannabis accessories. Famous Brandz Inc. is a dominant manufacturer of licensed lifestyle accessories, through partnerships with celebrities and entertainment companies including Snoop Dogg and Paramount Pictures. Famous Brandz’ products are sold to wholesalers and retailers around the world. Founded in 2009 and approved by the Canadian Franchise Association, Smoker’s Corner Ltd. is among Canada’s largest counter-culture chains with 12 locations. Kush West Distribution is in the process of becoming a cannabis wholesaler in the province of Saskatchewan. Based in Amsterdam since 2000, Grasscity.com is the world’s preeminent and most searchable online retailer of smoking accessories and cannabis lifestyle products with approximately 5.8 million site visits annually. With the deregulation of recreational cannabis for adult use across Canada, Canna Cabana Inc. and its 24 branded stores, is a sizeable retail business with a sophisticated yet playful customer experience. KushBar Inc. is a retail cannabis joint venture with 2 locations in Alberta, offering a modern experience that is focused on the growing customer bases in Alberta and Ontario.

For more information about High Tide Inc., please visit www.hightideinc.com and its profile page on SEDAR at www.sedar.com.

Forward-Looking Information

Certain statements in this news release are forward-looking information or forward-looking statements. Such information and statements, referred to herein as “forward-looking statements” are made as of the date of this news release or as of the date of the effective date of information described in this news release, as applicable. Forward-looking statements relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (generally, forward-looking statements can be identified by use of words such as “outlook”, “expects”, “intend”, “forecasts”, “anticipates”, “plans”, “projects”, “estimates”, “envisages, “assumes”, “needs”, “strategy”, “goals”, “objectives”, or variations thereof, or stating that certain actions, events or results “may”, “can”, “could”, “would”, “might”, or “will” be taken, occur or be achieved, or the negative of any of these terms or similar expressions, and other similar terminology) are not statements of historical fact and may be forward-looking statements.

Such forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to the ability of High Tide to execute on its business plan and that High Tide will receive one or multiple licenses from Alberta Gaming, Liquor & Cannabis, British Columbia’s Liquor Distribution Branch, Liquor, Gaming and Cannabis Authority of Manitoba, Alcohol and Gaming Commission of Ontario or the Saskatchewan Liquor and Gaming Authority permitting it to carry on its Canna Cabana Inc. and KushBar Inc. businesses. High Tide considers these assumptions to be reasonable in the circumstances. However, there can be no assurance that any one or more of the government, industry, market, operational or financial targets as set out herein will be achieved. Inherent in the forward-looking statements are known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements, or industry results, to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements.

The forward‐looking statements contained herein are current as of the date of this news release. Except as required by law, High Tide does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances. Any and all forward-looking statements included in this news release are expressly qualified by this cautionary statement, and except as otherwise indicated, are made as of the date of this news release.

SOURCE High Tide Inc.

For further information: please contact Nick Kuzyk, Chief Strategy Officer & SVP Capital Markets at High Tide Inc.; Tel: (403) 265-4207; Email: Nick@HighTideInc.com; Web: www.HighTideInc.com.

The post High Tide Exceeds $797,000 in Systemwide Retail Cannabis Store Sales for the 3-Day Period Celebrating the First Anniversary of Legalization appeared first on CannabisFN.

InnoCan Pharma Plans to Enter CBD Beauty Market with Launch of InnoCan Branded Cosmetic Products in H1/20

CALGARY, ALBERTA and TEL AVIV, ISRAEL / ACCESSWIRE / October 21, 2019 / InnoCan Pharma (“InnoCan” or the “Company“) (CSE:INNO) announced Tel Aviv, Israel today that it plans to accelerate its entry into the lucrative and growing CBD beauty market. InnoCan’s R&D team, led by Nir Avram, a senior pharmaceutical scientist with more than 30 years experience, is developing a line of cosmetics containing CBD offering several high-quality products including anti aging facial oils, facial serums, eye serums, facial creams, facial masks, body oils and body lotions.

Iris Bincovich, InnoCan’s CEO, said, “The CBD cosmetic could be a significant market for InnoCan and we have been working on planning and developing a cosmetic line for sometime. We are very excited by the products we are planning for a commercial launch in the first half of 2020.”

According to a recent market study published by Adroit Market Research in August 2019, the worldwide cannabidiol (such as CBD) cosmetics market was valued at USD 588.64 million in 2018 and is anticipated to grow at a CAGR of 31.3% over the next seven years.

View photos

About InnoCan Pharma Corporation

InnoCan brings pharmacological rigour to the burgeoning CBD marketplace. The founders and officers of InnoCan all have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally. InnoCan’s business has three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) research, development, marketing, distribution and sales of InnoCan-branded OTC pharmaceutical products; (ii) research and development of non-pharmaceutical products for third parties in exchange for fees and/or royalties; and (iii) research and development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. http://innocanpharma.com/

For further information, please contact:

For InnoCan Pharma Corporation:

Iris Bincovich, CEO
+972-54-3012842
info@innocanpharma.com

For Investor Relations:

Proconsul Capital Ltd.
Andreas Curkovic
416-577-9927

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: InnoCan Pharma Corp

The post InnoCan Pharma Plans to Enter CBD Beauty Market with Launch of InnoCan Branded Cosmetic Products in H1/20 appeared first on CannabisFN.

HTC Announces Repricing of Private Placement

REGINA, Oct. 17, 2019 /CNW/ – HTC Extraction Systems (also the “Company” and/or “HTC“) (HTC: TSX-V) announces that it has repriced its “bought deal” brokered private placement initially announced on July 3, 2019 and amended on September 27, 2019 (the “Offering“). The private placement is being re-priced to more accurately reflect the current market price of the Company’s common shares (the “Common Shares“).

Under the terms of the Offering, Canaccord Genuity Corp. will act as sole bookrunner and lead underwriter on behalf of a syndicate of underwriters (collectively, the “Underwriters“), and purchase, on a “bought deal” private placement basis, 25,000,000 units of the Company (the “Units“) at a price of C$0.40 per Unit (the “Offering Price“) for aggregate gross proceeds of C$10,000,000.

Each Unit will consist of one Common Share in the capital of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant“). Each Warrant will be exercisable to acquire one Common Share (a “Warrant Share“) at an exercise price of C$0.70 per Warrant Share for a period of 36 months from the closing of the Offering.

All securities issued or issuable under the Offering will be subject to a statutory hold period lasting four months and one day following the closing of the Offering.

The repriced Offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the conditional approval of the TSX Venture Exchange. The Offering is expected to close on or about October 22, 2019.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE RELEASE.

HTC corporate developments can be followed on www.htcextraction.com and is traded under the symbol HTC.

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended and may not be offered or sold In the United States or to, or for the account of benefit of, US persons absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

This press release contains “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward- looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of HTC. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur or be achieved. This press release contains forward-looking statements pertaining to, among other things, the timing and ability of the Corporation to close the Offering, if at all and the timing and ability of the Corporation to satisfy the listing conditions of the TSX Venture Exchange.

Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by HTC and described in the forward-looking information contained in this press release.

Although HTC believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance.

SOURCE HTC Extraction Systems

Lionel Kambeitz, HTC Extraction Systems, Tel: 306‐359‐3448, E‐mail: lpk@htcextraction.comCopyright CNW Group 2019

The post HTC Announces Repricing of Private Placement appeared first on CannabisFN.

Indiva Announces Expansion Approval From Health Canada

Newly-licensed space doubles flower capacity and provides rooms for Indiva to process edibles

LONDON, ON, Oct. 21, 2019 /CNW/ – Indiva Limited (the “Company” or “Indiva“) (TSXV:NDVA) (OTCQX:NDVAF) is pleased to announce that Health Canada has approved its licence amendment, adding 10,000 square feet of production space, including three new grow rooms and two additional processing rooms. This additional square footage will, subject to applicable regulatory approvals, be used to manufacture edibles, increase Indiva’s flower production capacity, and enable new growth in the production, manufacturing, processing and refinement arms of the business.

“We are excited to open up these five additional rooms. This new space significantly increases Indiva’s revenue potential by adding more capacity to our production, processing and refinement operations,” Niel Marotta, Indiva’s President and Chief Executive Officer, said. “The approval of this licence amendment powers the next step in our journey; infusing our cannabis into gourmet chocolate as well as other derivative products. We stand committed to following Health Canada’s regulations and are proud to receive clearance to continue forward with our strategy to meet the expectations of our supply agreements with provincial wholesalers. We look forward to bringing our exceptional cannabis and cannabis-infused products to more Canadians.”

Indiva intends to begin populating its three new flower rooms immediately. The cannabis grown in this space is expected to be turned into flower, pre-rolls, oil and distillate. The two newly-licensed processing rooms are expected to be dedicated to Indiva’s pre-roll production and chocolate manufacturing operation.

Indiva is also pleased to announce plans to submit its evidence package to Health Canada for the final phase of its London, Ontario facility by the end of October. Once licensed, this will provide an additional 10,000 square feet of processing space.

ABOUT INDIVA
Indiva’s global family of cannabis brands set the standard for quality and innovation. Indiva aims to bring its exceptional portfolio of products to Canadians and cannabis enthusiasts around the world as laws permit. Indiva’s production facility, based in London, Ontario, includes aeroponic, environmentally-conscious grow rooms and a nearly completed extraction and manufacturing space, which will be able to process 70 tonnes of biomass annually and produce safe, high-quality cannabis-infused edibles. In Canada, Indiva will produce and distribute Ruby® Cannabis Sugar, Sapphire™ Cannabis Salt and Ruby® Gems, as well as the award-winning Bhang® Chocolate, and other derivative products through licence agreements and joint ventures. Click here to connect with Indiva on social media and here to find more information on the Company and its products.

DISCLAIMER AND READER ADVISORY
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has in any way passed upon the merits of the Transaction and neither of the foregoing entities accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the Company’s future operations, future product offerings and entry into additional markets, changes to laws and regulations in Canada and internationally, and compliance with applicable regulations. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include the parties being able to obtain the necessary regulatory and other third parties’ approvals and licensing and other risks associated with regulated entities in the cannabis industry. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

SOURCE Indiva Limited

For further information: MEDIA CONTACT: Kate Abernathy, Vice President of Communications, Phone: 613-296-5764, Email: kabernathy@Indiva.com; INVESTOR CONTACT: Steve Low, Investor Relations, Phone: 647-620-5101, Email: slow@Indiva.com

The post Indiva Announces Expansion Approval From Health Canada appeared first on CannabisFN.

European Update: Canopy Growth Secures Exclusive Opportunities in the UK & Luxembourg

Receives first UK licence for a storage and distribution facility dedicated to medicinal cannabis, under the MHRA ‘specials’ program for unlicensed medicines

Wins exclusive contract to supply medical cannabis in Luxembourg, connecting country to Canopy Growth’s European network

SMITHS FALLS, ON, OXFORD, England and FRANKFURT, Germany, Oct. 21, 2019 /CNW/ – Canopy Growth Corporation (TSX: WEED), (NYSE: CGC) (“Canopy Growth” or the “Company”), is pleased to provide updates on key developments in the United Kingdom (“UK”) and Luxembourg. In these countries, the Company’s pharmaceutical business, Spectrum Therapeutics, continues to expand its sophisticated, pan-European cannabis production and distribution network serving the needs of physicians and their patients. Canopy Growth is committed to transforming healthcare in Europe by providing better access to medical cannabis treatments that have the potential to improve the lives of millions of patients.

United Kingdom

In the UK, Spectrum Therapeutics has received licences from the Medicines and Healthcare products Regulatory Agency (“MHRA”) and Home Office to store and distribute cannabis-based medicinal products (“CBMPs”). The first of its kind facility in the UK is designed to reduce prescription delivery time, a key development as the company establishes its footprint in the UK. The licence also allows the company to import CBMPs to the UK directly from Spectrum’s European and global networks, optimizing its supply chain and reducing overheads, without need for third-party suppliers.

Cosmo Feilding Mellen, Managing Director, Spectrum Therapeutics in the UK, said

“Medicinal cannabis has been available in the UK for less than twelve months, and in that time, we have established cost-effective UK infrastructure to meet the needs of patients.”

Continued Mellen, “We are delighted to have been granted licences from both the MHRA and Home Office in order to provide a solution to one of the most significant barriers for access in the UK. We are actively working with regulators to find the best way to ensure we can deliver continuous treatment to patients within the framework that exists.”

Spectrum Therapeutics passed a rigorous preliminary inspection from the MHRA to receive a licence. The company will continue to work closely with the MHRA and the Home Office to maintain the agreed terms, ensuring that CBMPs can be stored at volume in the UK under the highest standards of practice.

Luxembourg

Spectrum Therapeutics has become the exclusive supplier of medical cannabis to the Grand Duchy of Luxembourg (“Luxembourg”). The contract will see Luxembourg receive medical cannabis from Spectrum’s licensed facilities in Denmark and around the world until December 31, 2021.

In 2018, the Government of Luxembourg unanimously passed a law to decriminalize medical cannabis for patients with severe unmet needs. Under the new legislation, general practitioners and specialist medical professionals who have undertaken specific training are able to prescribe cannabis to eligible patients in Luxembourg. Patients with severe needs include those living with cancer, neuro-degenerative, chronic and painful diseases.

“We are proud to share news of this decision from the government of Luxembourg, connecting patients to medicine supplied through our European platform,” said Paul Steckler, Co-Managing Director of Europe, Canopy Growth. “Luxembourg is a country with big ambitions when it comes to medical cannabis, and we are excited to have earned the opportunity to supply this new market.”

Canopy Growth has received all authorizations required to import medical cannabis into Luxembourg and has completed the first shipment of medicinal cannabis to Luxembourg’s Division de la Pharmacie et des Medicaments.

Here’s to Future Growth (in Europe).

About Canopy Growth Corporation
Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through Canopy Growth’s subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. Canopy Growth has operations in over a dozen countries across five continents.

Canopy Growth’s medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics.

Canopy Growth operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships.

From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 4.7 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to leadership changes and transitions. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information and such risks contained in the Company’s annual information form dated June 27, 2018 and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise, unless required by applicable securities laws.

SOURCE Canopy Growth Corporation

For further information: Media Contact: Caitlin O’Hara, Corporate Communications Manager, Caitlin.Ohara@canopygrowth.com, 613-291-3239; Investor Contact, Tyler Burns, VP, Investor Relations, Tyler.Burns@canopygrowth.com, 855-558-9333 ext. 122

Related Links

canopygrowth.com

The post European Update: Canopy Growth Secures Exclusive Opportunities in the UK & Luxembourg appeared first on CannabisFN.

MJardin Group Provides Update on Cannabella Acquisition

TORONTO and DENVER, Oct. 18, 2019 (GLOBE NEWSWIRE) — MJardin Group, Inc. (“MJardin” or “the Company”) (CSE: MJAR) (OTCQX: MJARF), a leader in premium cannabis production, announced today that the Company has agreed to issue 741,765 common shares in the capital of MJardin (the “Common Shares”) to the seller of Carson City Agency Solutions LLC (which does business under the trade name Cannabella), as a non-refundable pre-payment of the $4.5 million USD purchase price, of which $500,000 USD was paid as cash consideration at the time of execution for the previously announced acquisition of Cannabella.

The Common Shares are being priced at $0.715 CAD per Common Share and will reduce the purchase price payable on closing of the Cannabella acquisition by $400,000 USD.  The $3.6 million USD balance of the purchase price will be payable in Common Shares upon closing, with the pricing of such Common Shares based on the trading price of MJardin shares at the time of closing.

In consideration for the pre-payment of a portion of the purchase price, MJardin will receive certain benefits under its management agreement with Cannabella that it would otherwise have had to wait until closing to receive.  Completion of the Cannabella acquisition is subject to customary closing conditions, including regulatory approval.

The Cannabella acquisition provides extraction capabilities to MJardin’s current cultivation operations in Nevada, allowing the Company to use a portion of its cultivation output for extracts towards edibles, topicals and other potential product lines.  Cannabella’s products are already in approximately 50 of the 68 retail dispensaries in Nevada, and the Company anticipates that it will be able to expand its footprint to many of the new dispensaries being opened following the recent grant of approximately 50 additional licenses.

About MJardin Group
MJardin is a cannabis management platform with extensive experience in cultivation, processing, distribution and retail. For over 10 years, MJardin has refined cultivation methodologies, developed state of the art facilities and implemented vertical integration for and on behalf of license owners. MJardin is based in Denver, Colorado and Toronto, Canada. For more information, please visit www.mjardin.com.

The CSE has not in any way passed upon the merits of and has neither approved nor disapproved the contents of this news release.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Information
This news release contains forward-looking information based on current expectations. Statements about, among other things, future developments and the business and operations of MJardin, our production capacity, our production results, the receipt of any pending regulatory approvals or licenses, the growth of our global footprint and our intentions to leverage our scale for continued organic growth and to pursue strategic investments are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such factors include, but are not limited to: our ability to identify and pursue growth, financing and other strategic objectives, and the regulatory and economic environments in the jurisdictions we operate or intend to operate or invest in. Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that the proposed acquisition will occur and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. MJardin assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

 INVESTOR CONTACT:

Ali Mahdavi                                                                Pat Witcher
Capital Markets & Investor Relations                        Chief Operating Officer
416-962-3300                                                            720.613.4019
Ali.mahdavi@MJardin.com                                        Pat.Witcher@Mjardin.com

The post MJardin Group Provides Update on Cannabella Acquisition appeared first on CannabisFN.

StartUp Calgary Selects FluroTech as One of This Year’s Top Startups

CALGARY, Alberta, Oct. 21, 2019 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF), (“FluroTech” or the “Company”), a technology company focused on the analytical cannabis and hemp testing market, is pleased to announce it has been selected as one of the top 15 up and coming startups of the year by StartUp Calgary. As a result of its selection FluroTech will have a booth at the 10th Annual Launch Party at The Big Four in Stampede Park in Calgary on Tuesday, November 12 from 6:00 PM to 9:00 PM. Anyone interested in learning more about FluroTech or any of the other great Calgary startups are encouraged to join the evening’s festivities.

“We appreciate the community nominations and the recognition by StartUp Calgary of our efforts. Transitioning from the research stage to sales is a major milestone for the Company this year,” stated Danny Dalla-Longa Chief Executive Officer. “We are excited to showcase FluroTech and the CompleTest™ amongst an amazing cohort of startups, entrepreneurs, community leaders and investors.”

FluroTech’s proprietary spectroscopy-based technology was originally developed by Dr. Elmar Prenner at the University of Calgary and is now being commercialized for the cannabis and hemp industries. The CompleTest™, an affordable and easy-to-use analytical testing device, allows growers, brokers, and extractors of cannabis to reliably and accurately test for potency or contaminants in a fast and affordable manner.

About FluroTech (TSX-V: TEST) (OTCQB: FLURF)

FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech’s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples. Using the technology that was developed at the University of Calgary, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.

To learn more, visit www.FluroTech.com.

Contact Information

Danny Dalla-Longa
Chief Executive Officer
403.680.0644
danny@flurotech.com

FluroTech Ltd.
7 – 3535 Research Road NW
Calgary, AB T2L 2K8
info@flurotech.com

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the Flurotech’s presence at the Startup Calgary Launch party and the benefits thereof. The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties and the need and demand for the CompleTest™ to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to, adverse market conditions and regulatory and other risks associated with the cannabis and hemp industries in general, users of the Company’s the CompleTest™ failing to achieve the anticipated benefits of the product, competition from other developers of similar technology , failure to reach commercialization of the technology, and failure for the products anticipated market to develop. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive.

The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.

 

Primary Logo

The post StartUp Calgary Selects FluroTech as One of This Year’s Top Startups appeared first on CannabisFN.

Tech Guru Steering the Ship for CanIdeal’s Innovative Cannabis B2B Platform; Plus Exclusive Interview with CEO Joseph Farruggia

Does success really breed success? According to researchers at SUNY Stony Brook in a 2014 study, it indeed does. While the study mostly tested the basic principle without merit given for bona fide accomplishments, every company wants to have leadership at the helm with deep experience and a track record of accomplishments. In that case, it would stand to reason that the likelihood of success is further increased from the 9-31% increase the research showed.

Fast forward to 2019 enter the exploding legal cannabis market.

Those that have been involved in the cannabis space for the better part of the last decade, particularly in the last couple years, have seen something pretty amazing happen within the once clandestine industry. With cannabis now legal in 33 U.S. states for medical purposes and 11 states and Canada for recreational use, the market has moved from the back alley to the board room. Many successful businessmen, business women, entrepreneurs, athletes and celebrities have very publicly made the leap into legal cannabis.

Accredited?Click here to see company investor deck

That’s the type of opportunity where skilled business acumen, financial astuteness, experience with new markets and corporate networking skills are worth their weight in gold. We’re talking about the type of opportunity these men and women will never see again in their lifetime and they don’t want to miss out.

How big? Industry-research experts at Arcview Research and partner BDS Analytics see the legal cannabis market (which doesn’t include cannabinoid and related product sales) growing from $3.4 billion in 2014 to $40.6 billion in 2024.

Joseph Farruggia wasn’t going to miss out either and has now brought his skill set to the new cannabis business-to-business platform, CanIdeal.

CanIDeal? Yes You Can.

Joseph Farruggia, CanIdeal’s CEO and President, is an investment industry veteran that founded CanIDeal after several notable successes earlier in his career. His vision was clear: to build the first B2B e-commerce platform serving the entire cannabis industry, bringing together growers, processors, technology accessory makers and distributors into one network to efficiently and legally transact cannabis-related business.

Accredited?Click here to see company investor deck

As Mr. Farruggia told CFN Media in a recent interview at the Cannabis World Congress and Business Expo in Los Angeles, “We have a B2B platform for the entire cannabis industry so that anyone in the industry can ‘come to the party,’ establish a brand and sell on a wholesale level across the country.”

 

 

CanIdeal is a robust solution to the huge problem of the cannabis industry being extremely fragmented because legislative framework underpinned by marijuana being a Schedule I drug at the federal level.

Owing to federal prohibition, states are left to craft their own laws applicable within their borders, all the while understanding that interstate commerce of cannabis isn’t possible and federally insured banks are subject to federal laws when providing banking services to an illicit drug. At the same time, with the passage of the 2018 Farm Bill late last year, hemp – defined as cannabis essentially free of the psychoactive THC (<-0.3%) – became legal at the start of 2019. To wit, cannabidiol (CBD) derived from hemp is open to interstate commerce.

The CanIDeal platform takes all this into account, using geo-fencing to recognize where companies are located. From there, potential supply chain agreements can be presented within the laws of the respective state. Simply, CanIdeal is designed to bridge all the gaps and simplify the byzantine nature of coast-to-coast regulations while simultaneously providing opportunities for companies to sell their products and services at the wholesale level and forge new business relationships. All companies can use the B2B platform for free, with CanIdeal taking a small percentage of each transaction conducted through the system.

Letting buyers buy for free and sellers to list for free is a key differentiator in making the CanIDeal platform neutral and a true open, digital marketplace for companies nationwide, according to Farruggia.

No one else has done this at the scale of CanIDeal.

The Brainchild of Farruggia

Joseph Farruggia is well rounded, to say the least. He has extensive experience in the capital markets and investor relations, serving previously as Director of Sales and Advertising for World Perspective Communications, where he was responsible for the launch and all aspects of Money World Magazine and Money World Investment Conferences. He also honed his Corporate America skills as the Investor Relations Specialist at Atlantic Capital Corp. and Wall Street Marketing Group. In this capacity, Farruggia utilized his network and communication abilities to raise capital for companies listed on national exchanges (i.e. NASDAQ, American Stock Exchange) and international markets by creating demand-side pull.

Accredited?Click here to see company investor deck

Farruggia is an entrepreneur too, pioneering corporate branded Wi-Fi for the restaurant sector. He can stake this claim as a co-founder of Cafe.com, Denny’s (NASDAQ: DENN) Wireless Internet. Serving as VP of Business Development for Café.com, Farruggia negotiated the company’s position as the sole approved wireless internet provider throughout the Denny’s franchise and then through Jack In The Box (NASDAQ: JACK) and Dunkin Donuts (NASDAQ:DNKN) quick-serve restaurants before selling Café.com to then publicly-listed ICOA, Inc.

Moreover, Farruggia co-founded Siddha Flowers, the maker of a line of flower essence products sold in Whole Foods, T.J. Maxx (NYSE: TJX), The Vitamin Shoppe (NYSE: VSI) and Sprouts, amongst other places. Today, the brand has products for teeth and gums, stress, memory and more. On that point, Siddha CEO, Stan Deland, sits on the CanIdeal Board of Advisors.

If that wasn’t enough, he is accomplished with the silver screen. Farruggia was the screenwriter for profitable feature films, including Baby Face Nelson starring Academy Award Winner F. Murray Abraham as Al Capone and C. Thomas Howell as Lester Gillis, better known as “Baby Face Nelson”. He also co-wrote Born Bad with Jeff Yonis, which starred Corey Feldman and James Remar.

As it happens, the genesis of CanIDeal occurred while Farruggia was working as a writer and a producer he was collaborating with, who also was a cannabis broker, heard Farruggia’s B2B idea and explained that no such platform existed. With that, Farruggia got to work and CanIdeal was born.

Farruggia has said that he only intends to serve as chief executive of CanIDeal during the initial launch, which ultimately began in May with a reverse merger that left CanIDeal the surviving entity. Farruggia is on the hunt for an experienced CEO to spearhead growth in the future.

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

 

The post Tech Guru Steering the Ship for CanIdeal’s Innovative Cannabis B2B Platform; Plus Exclusive Interview with CEO Joseph Farruggia appeared first on CannabisFN.

ManifestSeven Expands into Southern California’s Market

California is on track to post a record $3.1 billion in legal cannabis sales this year, according to Arcview Market Research and BDS Analytics, despite troublingly high taxes and licensing challenges that make it difficult to compete with black market products. By comparison, the same analysts expect Canada’s entire market to bring in just $1.1 billion this year, making the single state’s market nearly three times larger.

ManifestSeven, formerly known as MJIC, is building California’s first integrated omni-channel platform for legal cannabis, merging compliant distribution with a retail superhighway. The goal is to transform the cannabis purchasing experience from an antiquated cash-only retail visit to a streamlined buying experience that mirrors that of Amazon.com Inc. (NASDAQ: AMZN) — and it’s starting in densely populated Orange County.

Interested in ManifestSeven? Sign up to receive a free going public alert

In this article, we will take a look at ManifestSeven’s focus on Orange County and why it makes an excellent springboard to capitalize on the entire state market.

Starting with Distribution

ManifestSeven began its move into Southern California by establishing a Long Beach distribution facility earlier this year. In early April, the company was granted a temporary license by the State of California Bureau of Cannabis Control in connection with the facility, which is designed to serve as its Southern California distribution hub serving Los Angeles, San Diego and other cities within Orange County.

The new facility will connect its Northern California operations in Brisbane and Oakland with Southern California, helping it reach the vast majority of the state. The company estimates in its investor presentation that its hubs will be able to service almost 90%  of California’s population or about 35 million people across ten major markets there. That’s equivalent to a licensed producer achieving 94% Canadian penetration.

The company’s long-term goal is to become the Amazon.com of the cannabis industry by merging distribution with a seamless retail platform to simplify the purchasing experience.

Interested in ManifestSeven? Sign up to receive a free going public alert  

Building a B2C Presence 

Orange County is the sixth most populous county in the United States and boasts one of the country’s highest median incomes. With beautiful beaches and temperate climate year-round, it’s also an extremely popular tourist destination, attracting millions of visitors every year. These attributes make it an attractive location to start building a cannabis retail and distribution network that will eventually stretch across the state.

In August, the company acquired the Haven dispensary in Santa Ana — the only municipality in Orange County to issue cannabis retail licenses. This has since been rebranded to Weden, M7’s fully integrated retail arm, with this particular dispensary to serve as the flagship location.

The Weden business-to-consumer brand encompasses brick-and-mortar retail and delivery operations throughout the region, via a sophisticated e-commerce site and its 1-800-CANNABIS customer service center.

Weden Santa Ana owns one of just 30 allowable licenses permitting adult-use cannabis sales, as well as a provisional retail license issued by the State of California Bureau of Cannabis Control. With its proximity to four major freeways, the dispensary offers convenient access to the safest, highest-quality cannabis products to more than two million residents over the age of 21, as well as on-demand delivery and subscriptions.

The retail dispensary and its existing customer base dovetails nicely with the company’s existing cannabis delivery service and MyJane subscription service, which enables customers to easily become repeat buyers without having to physically visit a dispensary location — including customers that may visit the dispensary on vacation before returning home elsewhere in the state where dispensaries may not exist.

ManifestSeven, via its real estate investment vehicle Vicinity, has also recently completed the acquisition of the Santa Ana property. The sale-leaseback deal frees up critical working capital for M7 and is allowing the company to forge ahead with further expansion.

Looking Ahead

ManifestSeven is well-positioned to reach almost every corner of California with its distribution, retail and delivery services. As the company gears up to go public on the CSE, investors may want to follow these developments over the coming months.

Sign up to receive a free going public alert today!

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

The post ManifestSeven Expands into Southern California’s Market appeared first on CannabisFN.

PLUS Products Bolsters Research Expertise with the Addition of Chief Scientific Officer Dr. Ari Mackler

In the newly formed position, Mackler will lead evidenced-based edible cannabis research efforts across the entire PLUS Products portfolio of products

SAN MATEO, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) — Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) (the “Company” or “PLUS”) today announced the addition of Dr. Ari Mackler as the Company’s Chief Scientific Officer. Dr. Mackler brings 20 years of medical affairs, communications, and research experience in pharmaceutical, healthcare, and consumer goods industries.

Prior to joining PLUS, Mackler was vice president of clinical development for The Wonderful Company, where he led health & wellness initiatives to help establish the business as a global branded products leader. He also held previous positions with the multinational pharmaceutical company Merck & Co, the Almond Board of California, the International Tree Nut Council, the Nutritional Research & Education Foundation, and Stem Cell Resource.

Dr. Mackler’s position at PLUS will allow him to pursue research relationships and clinical trials with academic institutions and private partners in an effort to expand and contribute to consumer understanding of cannabis and the benefits it may provide. He will join an existing team of experts at PLUS that includes Michelin-star sous chefs, chemists, and food manufacturing experts who together have helped develop the number one and two best-selling cannabis products in the California1.

“Dr. Mackler has a long history of helping consumer product companies share a clear and scientifically backed narrative around product benefits. Cannabis is a performance category, and the most successful brands will be those that understand and are able to clearly communicate why their products work. There are few researchers of Dr. Mackler’s caliber in the cannabis industry today, and we believe he will play an invaluable role not only for PLUS, but as a though leader within the industry,” stated Jake Heimark, Co-Founder and CEO.

“I have been intrigued by cannabis for years and saw a huge opportunity to apply my scientific and consumer products background for PLUS to help validate and articulate how their products may help people live better lives,” stated Mackler. “I also believe scientifically-based education is vital to the future of the industry, and PLUS has focused their business processes in a way that ensures science is at the center of their product development DNA.”

(1)  Over the last twelve months by units and dollars of retail sales according to BDS Analytics

Availability

California THC: PLUS cannabis infused edibles are available in over 360 licensed retailers across the state of California.

Nevada THC: PLUS cannabis infused gummies are currently available several Las Vegas dispensaries, including 3 Medmen locations, and are expected to be rolled out to dispensaries across Nevada in the coming weeks.

National Hemp CBD: PLUS recently announced a line of 100% Hemp CBD infused gummies. They are available for purchase at plusproducts.com nationwide.

About PLUS

PLUS is a hemp and cannabis food company focused on using nature to bring balance to consumers’ lives. PLUS’s mission is to make cannabis safe and approachable – that begins with high-quality products that deliver consistent consumer experiences. PLUS is headquartered in San Mateo, CA with 80 employees.

For further information contact:

Jake Heimark
CEO & Co-founder
ir@plusproducts.com

Investors:

Blake Brennan
Director of Investor Relations
Blake@plusproducts.com
Tel +1 213.282.6987

Media:

Bill Harrison
Third Street Media Group
bill@thirdstreetmediagroup.com
Tel +1 213.712.8811

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:
This press release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (each, a “forward-looking statement”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur and include, but are not limited to, statements relating to: Dr. Mackler’s pursuit of research relationships and clinical trials with academic institutions and private partners; and the expectation that PLUS cannabis infused gummies are expected to be in dispensaries across Nevada in the coming weeks.

These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the success of the Company’s investments, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of the Company’s products, customer experience and retention, the continued development of adult-use sales channels, managements estimation of consumer demand in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete capital projects and facilities improvements, the ability to expand and maintain distribution capabilities, the impact of competition, the ability of the Company to implement initiatives and the possibility for changes in laws, rules, and regulations in the industry. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Primary Logo

The post PLUS Products Bolsters Research Expertise with the Addition of Chief Scientific Officer Dr. Ari Mackler appeared first on CannabisFN.

THC purchases an additional lot in its current Kelowna location

VANCOUVER, Oct. 21, 2019 /PRNewswire/ – THC BioMed Intl Ltd. (“THC” or the “Company“) (CSE: THC) announces that it has purchased, through its subsidiary THC BioMed Ltd., an additional strata lot in the industrial complex in Kelowna it currently occupies.

THC previously announced the purchase of additional strata units in the same building in July, April, March and January of this year and in December, October, and June of 2018. THC purchased this property as a part of its expansion plan due to high demand for its products. The new strata lot will be used for production purposes.

The purchase price was $391,500 plus fees and taxes, for a total of $400,148.82. THC purchased the strata lot for cash and did not require a mortgage.

About THC

THC is an ACMPR Licensed Producer and Canada’s largest supplier of legal Cannabis Genetics. THC is on the leading edge of scientific research and the development of products and services related to the medical cannabis industry. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry. Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC.  Forward-looking information is based on certain key expectations and assumptions made by the management of THC.  In some cases, you can identify forward-looking statements by the use of words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions.  Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct.  Forward-looking statements contained in this press release are made as of the date of this press release include that (a) THC purchased this property as part of its expansion plan due to high demand for its products, (b) the property will be used for production purposes and (c) THC will be in the forefront of this rapidly growing industry. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The post THC purchases an additional lot in its current Kelowna location appeared first on CannabisFN.

Zenabis Provides Operations Update for September 2019

VANCOUVER, Oct. 21, 2019 /CNW/ – Zenabis Global Inc. (TSX:ZENA) (“Zenabis” or the “Company“) is pleased to provide an update on its recent facility construction and licensing activities and recent cannabis production results.

Highlights:

  • With respect to production results:
    • Cultivation output in September 2019 was 2,089 kg of dried cannabis, with production at Zenabis Atholville outperforming its revised design capacity by 21.8% (the Performance Ratio1).
    • Cultivation output of 2,089 kg of dried cannabis was 21.2% greater than Zenabis’ revised forecast output (as updated on August 6, 2019) of 1,731 kg of dried cannabis.
  • Zenabis submitted a license amendment application for Zenabis Langley’s existing cultivation license on September 27, 2019 to include additional growing areas totaling 101,300 sq. ft. for Zenabis Langley – Part 2A. Zenabis’ licensed annual production capacity is expected to increase by 39,400 kg to 96,400 kg once this license amendment is approved by Health Canada.
  • Zenabis continues to focus on construction and licensing of Zenabis Langley. Zenabis has revised its construction timelines at Zenabis Langley to split Zenabis Langley – Part 2B into two phases (Zenabis Langley – Part 2B and Zenabis Langley – Part 2C) in order to preserve cashflow given current market conditions and reduce ramp-up risk, among other reasons detailed below. Zenabis expects to submit a license amendment for Part 2B in November 2019 (14,800 kg of licensed annual production capacity). Zenabis expects to submit a license amendment for Part 2C in February 2020 (32,000 kg of licensed annual production capacity) to the extent this is justified by market demand at economic prices. Zenabis’ total annual cultivation capacity is expected to increase to 143,200 kg of dried cannabis on completion of licensing at Zenabis Langley early in the second quarter of 2020.

Andrew Grieve, Chief Executive Officer of Zenabis, stated, “We continued to see strong cultivation results in September, with output exceeding our forecast of 1,731 kg by 21.8%. Our Performance Ratio decreased month over month as a result of the significant number of harvests from newly licensed rooms in the month (five of the 10 harvests). The Performance Ratio for newly licensed rooms harvested in September was 14.2% while the Performance Ratio for rooms that had previously been operated was 30.0%. Although the variety of cultivation approaches and rapid scale-up at Zenabis Atholville continues to cause room by room variance, steady-state yields for each cultivar are expected in the near-term, with general steady-state operations expected at Zenabis Atholville by the end of 2019.

“Since our last update, we increased our licensed annual cultivation capacity to 57,000 kg and submitted a licence application that is expected to increase our licensed annual production capacity by 69%, from 57,000 kg to 96,400 kg,” continued Andrew Grieve, Chief Executive Office of Zenabis. “While the timeline revision for Zenabis Langley will delay achieving full design capacity at the facility, we expect to have 96,400 kg of capacity licensed and operational by the end of 2019 with approval of the Zenabis Langley – Part 2A amendment. By early in the first quarter of 2020, we expect to have 111,200 kg of capacity licensed and operational with the approval of the Zenabis Langley – Part 2B amendment.”

_________________________

1

To better reflect the actual performance of its facilities, the Company reports a Performance Ratio, calculated as follows: after each harvest, Zenabis calculates the dry weight cannabis output for each room (the “Total Output”), taking into account the amount of days in production through a combination of: (1) the amount of flower room days used (including turnaround time) for that room; and (2) the amount of flower-room equivalent days required from other flower rooms in support of that harvest (together the “Effective Flower Room Equivalent Days”). Zenabis then divides the Total Output by the Effective Flower Room Equivalent Days in order to produce the “Effective Yield Per Day” for each room, and then divides the Effective Yield Per Day by the Design Capacity Yield Per Day for each room in order to determine actual performance versus the Design Capacity Yield Per Day (this ratio being the “Performance Ratio”). Zenabis believes that the Performance Ratio will provide investors with the best measure of actual cultivation performance versus Zenabis’ published design capacity. Zenabis intends to update and publish updated design capacities for each of its facilities when a facility has harvested from all its flower rooms (with the update at that time reflecting the most recent performance from each flower room) and again, if required due to significantly different results, when a facility achieves consistent monthly performance at a level that is different from its published Design Capacity.  Zenabis revised its design capacity at Zenabis Atholville upwards by 35% (equal to Zenabis Atholville’s Performance Ratio for the three months ended June 30, 2019) from 34,300 kg per annum to 46,300 kg per annum. Zenabis no longer reports outperformance relative to original design capacity (the kg/day figure utilized to derive the 34,300 kg design capacity).

 

Cannabis Production Summary

In September 2019, Zenabis realized a total harvest weight of 2,089 kg of dried cannabis.

The amount harvested at Zenabis Atholville for the three months ending September 30, 2019 exceeded the revised design capacity of the flower rooms by an average of 25.7%, compared to 23.2% in the three-month period from June 2019 through August 2019. A month-to-month comparison of actual harvests compared with harvest forecast based on revised design capacity between January 2019 and September 2019 for Zenabis Atholville is provided in the table below.

Revised Design Capacity

Performance at Zenabis

Atholville

Jan

2019

Feb

 2019

Mar

 2019

Apr

2019

May

2019

June

2019

July

2019

Aug

2019

Sept

2019

Total

Actual Harvest Weight (kg)

474

480

518

809

908

756

1,238

1,912

2,089

9,184

Revised Design Capacity

Harvest Weight (kg)2

467

643

539

796

895

716

1,097

1,357

1,715

8,225

Difference (kg)

7

(163)

(21)

13

13

40

141

555

374

959

Difference (%) – Revised

“Performance Ratio”

1.5%

(25.3%)

(3.9%)

1.6%

1.5%

5.6%

12.9%

40.9%

21.8%

11.7%

2

The Revised Design Capacity Harvest Weight is based on the “design capacity” yield that Zenabis has disclosed to date.  This figure was derived by converting the actual square footage of flower room space and the forecast canopy for each specific flower room into a kilograms per room per day figure based on Zenabis’ historical yield data at the Zenabis Atholville facility based on the yield performance in the three months ending June 2019 for revised design capacity. The Revised Design Capacity Harvest Weight in the table above is the harvest weight that would have resulted if the Design Capacity Yield Per Day for a room was multiplied by the Effective Flower Room Equivalent Days, as defined under “Performance Ratio”. Zenabis has revised its design capacity at Zenabis Atholville upwards by 35% (equal to Zenabis Atholville’s Performance Ratio for the three months ended June 30, 2019) from 34,300 kg per annum to 46,300 kg per annum. Zenabis no longer reports outperformance relative to original design capacity (the kg/day figure utilized to derive the 34,300 kg original design capacity for Zenabis Atholville)

 

In September 2019, Zenabis completed 10 harvests at Zenabis Atholville. The average Performance Ratio for these harvests was 21.8% relative to the revised design capacity. In September 2019, Zenabis did not complete any harvests at Zenabis Stellarton or Zenabis Langley.

2019 Harvest Forecast – Zenabis Atholville, Zenabis Stellarton and Zenabis Langley Site A – Part 1

For its existing licensed facilities of Zenabis Atholville, Zenabis Stellarton and Zenabis Langley Site A – Part 1, Zenabis expects to produce approximately 16,7335 kg of dried cannabis from October 2019 through January 2020. Zenabis continues to expect to complete its first harvest from Zenabis Langley in November. Zenabis’ forecast harvest output in November includes 1,650 kg from Zenabis Langley. The following table sets out Zenabis’ estimated aggregate monthly harvests for Zenabis Atholville, Zenabis Stellarton and Zenabis Langley Site A – Part 1 for the remainder of 2019 and January of 2020.

July

2019

Aug

2019

Sept

2019

Oct

2019

Nov

2019

Dec

2019

Jan

2020

Total

Forecast (kg)3

1,212

1,579

1,731

3,758

5,199

4,200

3,576

21,255

Actual (kg)

1,238

1,996

2,089

5,323

3 

This forward-looking estimate of future harvest results is based on the following material assumptions: (1) Zenabis Stellarton and Zenabis Langley Site A – Part 1 operate at their published design capacity on a room by room basis for the cultivation space that is licensed and in cultivation at the forward-looking periods noted; (2) Atholville rooms operate based on the current flower schedule and at revised design capacity (a 35% increase relative to original design capacity); and (3) Cultivation commencement at Zenabis Langley Site A – Part 1 in September 2019.   

 

Zenabis intends to provide a monthly cultivation forecast for Zenabis Langley Site A – Part 2A and Zenabis Langley Site A – Part 2B upon receipt of all cultivation license amendments for these phases.

Cannabis Post-Harvesting and Packaging Discussion

The timeline from harvest to the point at which Zenabis completes a sale of that product ranges from a minimum of three weeks (in the case of a bulk sale to a licensed producer) to more than eight weeks (in the case of soft gel capsules which involve external extraction, processing, filling, packaging and shipment). Zenabis recognizes the revenue from completion of such sales in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.

In August 2019, Zenabis replaced its original packaging equipment (for bud jar filling) at Zenabis Atholville with new packaging equipment intended to achieve output of 30,000 units per day (equivalent to more than 90,000 grams per day at current average volumes per jar). During September 2019, the new packaging equipment was not able to achieve its expected output. Instead average output in September was 6,276 units per day, resulting in completed bud filling of only 517 kg (this excludes pre-roll packaging and bulk packaging). As a result, Zenabis was not able to package, ship and sell all of its product cultivated in August and September that had been destined for provincial counterparties, causing a delay in achieving the Company’s expected revenues. With focused troubleshooting, Zenabis has now achieved primary packaging output of 11,643 units per day, on average, during the 14 days ending October 20, 2019, with a maximum of 22,416 units per day. In addition, Zenabis has moved the original packaging equipment at Zenabis Atholville to Zenabis Stellarton and is in the process of ramping-up packaging at Zenabis Stellarton (bud filling commenced October 10, 2019 and pre-roll packaging commenced September 11, 2019). Zenabis expects that, as of November 2019, the Company will have surplus packaging capacity, and that there will be no further delays in the Company’s ability to package, ship and sell all of the product cultivated at Zenabis Atholville.

Currently, indicative demand from provincial counterparties exceeds forecast supply of both packaged flower and packaged pre-rolls for October 2019 through January of 2020 without further reductions in price. Indicative demand does not necessarily translate into actual demand, as the planning process with provincial counterparties may not result in firm volume indications until two weeks prior to a shipment, with purchase orders at times being finalized within days of shipments. As ramp-up of Zenabis’ facilities and the facilities of competitors occurs, Zenabis expects continued pressure on wholesale pricing to be applied by provincial counterparties.

In September, Zenabis packaged 650 kg of bulk product and shipped 190 kg, with the remainder held over for shipment to bulk counterparties in October to meet prepaid supply agreement commitments. Zenabis packaged 732 kg of flower and pre-rolls for provincial counterparties in September and shipped 462 kg. Zenabis also shipped 174 litres of oil products in September.

Construction and Facility Update

Zenabis Atholville

Now that construction is substantially complete4 at Zenabis Atholville, Zenabis is focused on operational improvements to reduce operating costs (increasing packaging automation, for example), improve post-harvest processing, increase yield, and improve packaging throughput.

Zenabis Langley

The first phase of Zenabis Langley (Zenabis Langley – Part 1) is licensed and operational. Since Zenabis’ August operations update was released, Zenabis has reached substantial completion of Part 2A4 and submitted a cultivation license amendment for this phase.

Zenabis remains focused on converting the remaining portion of Zenabis Langley but has revised its conversion plan for these phases to split Zenabis Langley – Part 2B into two phases (Zenabis Langley – Part 2B and Zenabis Langley – Part 2C). Zenabis has made this revision for the following reasons:

  • Focus on Cashflow Generation. By revising the timeline for the submission of Zenabis Langley’s final two flower rooms (Zenabis Langley – Part 2C), Zenabis expects to be able to reduce cashflow outflows for capital expenditure as Zenabis works to generate positive cashflow from operations.
  • Staggering Operational Ramp-Up. Further staggering the operational ramp-up at Zenabis Langley is expected to reduce the inherent issues that come with ramping up a facility of this size. As is illustrated by the packaging discussion above (regarding ramp-up at Zenabis Atholville), ramp-up challenges are possible in this industry. While Zenabis is focused on ramping up its facilities in a manner where any commercially possible action is taken to mitigate ramp-up risk, Zenabis believes that staggering the ramp-up at Zenabis Langley is in the best interest of the Company.
  • Defer Budget Overages. Zenabis recently identified that it expects to spend the entirety of its estimated amount remaining at Zenabis Langley (as forecast in Zenabis’ MD&A for the period ending June 30, 2019 at $13,700,000) upon completion of Part 2B. As a result, Zenabis expects capital expenditure amounts remaining to spend relating to Part 2C to be budget overages (estimated to be $4,000,000). This overage was driven by increases in equipment costs relating to HVAC equipment and automated tray tables. Zenabis has made the decision to defer this overage expenditure to a time when it can be funded by operating cashflow as opposed to cash on hand.

Zenabis expects this timeline revision to have the following impact on the cumulative capacity submitted for licensing at Zenabis Langley:

Month

Cumulative Capacity

Submitted for Licensing

(Original Timeline)

Cumulative Capacity

Submitted for Licensing

(Revised Timeline)

Difference

October 2019

49,300 kg

49,300 kg

November 2019

96,100 kg

64,100 kg

(32,000 kg)

December 2019

96,100 kg

64,100 kg

(32,000 kg)

January 2020

96,100 kg

64,100 kg

(32,000 kg)

February 2020

96,100 kg

96,100 kg

 

A summary of construction status by phase is provided below:

Phase

Design Capacity

Description

Part 1

9,900 kg

– Licensed and operational

Part 2A

39,400 kg

– Consists of 101,300 sq. ft. of flower room space (two flower rooms)

– Substantially complete

– License amendment submitted in September 2019

Part 2B

14,800 kg

– Consists of 38,000 sq. ft. of flower room space (one flower room)

– HVAC, flooring and shade screen installation is ongoing

– Security equipment and lighting installation is substantially complete

Part 2C

32,000 kg

– Consists of 82,200 sq. ft. of flower room space (two flower rooms) and

122,300 sq. ft. of other operational spaces (includes drying rooms,

packaging rooms, mother space and vegetation space)

– HVAC, flooring and shade screen installation is ongoing

– Security equipment and lighting installation is substantially complete

 

_________________________

4 

Zenabis defines substantial completion as the ability to undertake (subject to licensing) all production activities within the design capacity of the facility.

 

Zenabis Stellarton

On September 6, 2019, Zenabis received a cannabis processing license for Zenabis Stellarton. Zenabis commenced pre-roll production at Zenabis Stellarton during the week of September 9, 2019. Zenabis’ current pre-roll production capacity at Zenabis Stellarton is estimated at ~600 kg of pre-rolls per month. Zenabis intends to achieve output of 1,200 kg of pre-rolls per month at Zenabis Stellarton by November 2019, subject to market demand for pre-rolls.

In addition, as noted above, Zenabis has installed at Zenabis Stellarton the packaging equipment (for bud jar filling) previously used at Zenabis Atholville. Following completion of the ramp-up of this equipment, combined with the new packaging equipment in operation at Zenabis Atholville, Zenabis expects to have excess packaging capacity.

Zenabis Delta

Zenabis is currently in the process of constructing extraction and post-processing capacity, a product development lab, a formulation design lab, and a full ISO certified analytical testing lab at Zenabis Delta. This construction project is expected to be complete in the first half of 2020.

Licensing Update

Zenabis is currently in the process of various licensing applications for Zenabis Delta, Zenabis Langley, Zenabis Stellarton and the Zen Craft Grow program as outlined in the table below:

License Submission

Submission Month

Annual Design Capacity

Zenabis Delta – Analytical Testing

May 2019

N/A

Zen Craft Grow – Grower 1

July 2019

350 kg

Zenabis Langley – Part 2A

September 2019

39,400 kg

Zenabis Stellarton – Sales License

October 20195

N/A

Zenabis Langley – Part 2B

November 20195

14,800 kg

Zenabis Langley – Part 2C

February 20205

32,000 kg

5

Expected submission timeline subject to receipt of prior license or license amendment for each facility

 

Zenabis is currently using Zenabis Pitt Meadows, Zenabis Aldergrove and Zenabis Langley for the Company’s propagation and floral business, as well as hemp cultivation activities. All hemp cultivation at Zenabis Aldergrove that uses greenhouse space is currently not being used by the propagation and floral business, and thus will not have a negative impact on Zenabis’ propagation and floral business. Hemp cultivation will neither interfere with the planned cannabis cultivation activities at Zenabis Langley, nor will it reduce the cannabis cultivation design capacity of Zenabis Langley.

Please view the following link for Zenabis operational update presentation:
https://www.zenabis.com/docs/zenabis-operations.pdf

About Zenabis

Zenabis is a significant Canadian licensed cultivator of medical and recreational cannabis, as well as industrial hemp, and a propagator and cultivator of floral and vegetable products. Zenabis employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta, Aldergrove, Pitt Meadows and Langley, British Columbia; and Stellarton, Nova Scotia. In addition to gaining technologically advanced knowledge of plant propagation, the recent addition of state-of-the-art greenhouses in Langley, Pitt Meadows and Aldergrove provides Zenabis with 3.5 million square feet of facility space that can, if fully converted, be dedicated to cannabis production.

If all facility space at Zenabis Atholville, Zenabis Stellarton and Zenabis Langley is fully converted and dedicated to production, Zenabis will own, and have access to 635,000 square feet of high quality indoor cannabis production space, as well as 2.1 million square feet of greenhouse cannabis production space at its Langley facility, with this production strategically positioned on Canada’s coasts. Zenabis expects these facilities to have an annual design capacity of 143,200 kg of dried cannabis under its existing capital plan. These facilities, if fully built out and converted for cannabis production, would have an annual design capacity to yield approximately 490,800 kg of dried cannabis annually, for both national and international market distribution. An additional 700,000 square feet of greenhouse space will be used to continue the existing propagation business and produce industrial hemp, and can be converted to cannabis production at such a time that is beneficial to the strategic position of the Company. The Zenabis brand name is used in the cannabis medical market, while the Namaste and Blazery brand names are used in the cannabis adult-use recreational market, and the True Büch brand name is used for Zenabis’ kombucha products.

Forward Looking Information

This news release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding the future plans, costs, objectives or performance of Zenabis, or the assumptions underlying any of the foregoing. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the projected kilogram yield of licensed facility space and facility space in the process of, or scheduled for, construction and/or licensing; our expectations for future harvests; the expected timing and completion of current and planned conversion, expansion and optimization of our facilities, including Zenabis Atholville and Zenabis Langley; our expected budget for capital expenditures related to the conversion, expansion and optimization of our facilities, including Zenabis Atholville and Zenabis Langley; our plans for Zenabis Delta; the expected submissions of license amendment applications and site evidence packages; the licensing of our facilities and projected timing thereof; our expectations for our extraction projects, equipment and capacity; our expectations for processing output; our expectations regarding our packaging equipment; the timelines projected for the commencement of cultivation at Zenabis Langley; the effect of hemp cultivation on our cannabis cultivation abilities; and the expected content of future operational updates. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Zenabis’ control. These risks, uncertainties and assumptions include, but are not limited to, those described in the shelf prospectus dated April 9, 2019, a copy of which is available on SEDAR at www.sedar.com and could cause actual events or results to differ materially from those projected in any forward-looking statements. Furthermore, any forward-looking information with respect to available space for cannabis production is subject to the qualification that management of Zenabis may decide not to use all available space for cannabis production, and the assumptions that any construction or conversion would not be cost prohibitive, required permits will be obtained and the labour, materials and equipment necessary to complete such construction or conversion will be available. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Zenabis does not intend, nor undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws

For more information, visit: https://www.zenabis.com.

SOURCE Zenabis Global Inc.

View original content: http://www.newswire.ca/en/releases/archive/October2019/21/c8207.html

Media Relations: Email: media@zenabis.com, Phone: 1-855-936-2247; Investor Relations: E-mail: invest@zenabis.com, Phone: 1-855-936-2247Copyright CNW Group 2019

The post Zenabis Provides Operations Update for September 2019 appeared first on CannabisFN.

Sproutly Receives Flower Sales License from Health Canada and Launches Premium Cannabis Brand ‘CALIBER’

Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (“Sproutly” or the “Company”) is pleased to announce that the Company’s wholly-owned subsidiary Toronto Herbal Remedies Inc. (“THR”), a licenced producer and processor under the Cannabis Act, has received its flower sales licence from Health Canada effective October 16, 2019 (the “Flower Sales License”). The Flower Sales License will allow THR to sell dried cannabis flower products provincially and territorially in Canada through authorised distributors and retailers. The sales will commence through the launch of Sproutly’s premium cannabis brand CALIBER (“CALIBER”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005988/en/

“We are thrilled to receive our Flower Sales License from Health Canada. This is a huge milestone in our company’s history, as it allows us to bring to market our dried flower products into the hands of recreational consumers throughout the country,” said Keith Dolo, CEO & Director. “With our Flower Sales License, we are finally able to commercialize our CALIBER brand of premium cannabis products beginning with dried flower and are excited to share the vision and products that the team at THR worked very hard throughout the year to bring together.”

The Company has curated the CALIBER brand with the cannabis connoisseur in mind. With a high-quality manufacturing process, award-winning genetics and distinct premium packaging, the CALIBER brand will deliver a superior cannabis experience for Canadian consumers. Sproutly will commence the roll out the CALIBER brand and brand campaign in compliance with Health Canada’s promotional guidelines that will provide consumers and retailers with important product education and information, brand highlights, and the vision behind the brand.

About Sproutly Canada, Inc.

Sproutly’s core mission is to become the leading supplier to the cannabis beverage and edibles market. The Company’s Toronto based facility, licensed under the Cannabis Act, was built to cultivate pharmaceutical grade cannabis to supply a technological breakthrough in producing and formulating the first natural, truly water-soluble cannabis solution. Our water-soluble ingredients and our bio-natural oils will deliver revolutionary brands to international markets that are clamouring for well-defined commercial products. Sproutly’s business focus is to execute on partnerships with local and globally established consumer brands to leverage their existing customer bases, further expand brand loyalty, assist with marketing, and support distribution networks to deliver this scientific breakthrough with speed and efficiency worldwide.

For more information on Sproutly, please visit: www.sproutly.ca.

Forward-Looking Statements

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or believes regarding future events of management of Sproutly. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward‐looking statements”, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management’s expectations and intentions with respect to, among other things, timing relating to the formation of the Joint Venture, the qualities of the Infused Beverages and the Company realizing anticipated benefits and synergies from the Joint Venture. These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These assumptions, risks and uncertainties include, among other things, the Company’s inability to successfully develop and produce the Infused Beverages, the Company’s inability to obtain any necessary regulatory approvals, failure to complete or realize anticipated benefits and synergies from the Joint Venture; potential negative consumer, investor or public perception of a party’s respective current brand or company; changes in consumer preferences and product trends; and political, legal and regulatory uncertainty relating to cannabis products generally. In making the forward looking statements in this news release, the Company has applied several material assumptions, including without limitation, that the Company will be successful in completing the development and production of the Infused Beverages, the Company will obtain all applicable regulatory approvals from global jurisdictions including Health Canada and the Company will be able to successfully satisfy all of the conditions in the Joint Venture Agreement. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

Keith Dolo, Chief Executive Officer of Sproutly Canada, Inc.
Email: investors@sproutly.ca

The post Sproutly Receives Flower Sales License from Health Canada and Launches Premium Cannabis Brand ‘CALIBER’ appeared first on CannabisFN.

Goldenseed Files with SEC to Become First Private U.S. Cannabis Grower to Allow Early Stage Investment from General Public

SANTA CRUZ COUNTY, Calif.–(BUSINESS WIRE)–Goldenseed, a California lifestyle cannabis and hemp brand, whose first product line won the High Times’ Cannabis Cup for Best Pre-Roll in May 2019, today announced it filed with the U.S. Securities and Exchange Commission (SEC) to hold a stock offering. This offering will allow the general public to invest in Goldenseed at an early stage, which is typically only available to high net worth individuals and well-connected investors. Goldenseed expects to be qualified by the SEC to launch its offering online within the next 60-90 days. When it goes live, the general public will be given the opportunity to invest in Goldenseed for as little as $100.00. Goldenseed intends to use portions of the net proceeds from the stock offering toward capital improvements, debt reduction, marketing and general working capital.

Goldenseed Files with SEC to Become First Private U.S. Cannabis Grower to Allow Early Stage Investment from General Public

Tweet this

“We’re excited to provide a chance to invest in the California cannabis industry and to become part of the Goldenseed community,” said Scott Goldie, chief executive officer of Goldenseed. “I see this as similar to entering the wine industry in Napa in the early ‘70s, before it boomed.”

Goldenseed recently launched as a cultivator, manufacturer, and distributer of high-quality cannabis and hemp naturally grown in renowned Santa Cruz County, California. Goldenseed delivers pure cannabis in the form of proprietary seed strains, smokable blends, and oil and terpene extractions to a discerning clientele. The brand focuses on:

  • Sustainable Farming: Goldenseed’s Santa Cruz County farm is a model for the cannabis industry for clean growing, harvesting, and soil-building land stewardship with Envirocann certification. Goldenseed has also built a worm farm onsite with 16,000 pounds of red wiggler worms that create living soil, rich in microbial and fungal life that ultimately grows natural cannabis.
  • Facilities: Goldenseed’s cannabis cultivation at the Santa Cruz farm can grow as large as 440,000 square feet, potentially becoming one of the larger growers of greenhouse cannabis in California. By year’s end, Goldenseed’s hemp cultivation alone will span 90 acres of Santa Cruz farmland with over two acres of seed production.
  • Research and Development: Goldenseed looks to the future and constantly conducts pheno hunts, which are the cross-breeding and back-breeding of dozens of genetic strains to grow plants that resist disease, grow at the optimal speed, yield the most, and look, smell and taste better. This enables Goldenseed to extract the purest and most powerful terpenes from the plant, which are natural compounds that contribute to a plant’s taste and smell. Goldenseed also focuses on the latest research in CBD to THC ratios, to discover if there is any potential for health applications.

Goldenseed’s stock offering will be held under Regulation A, a law passed as part of the 2012 Jumpstart Our Business Startups (JOBS) Act that allows small companies to raise capital by selling stock online through equity crowdfunding. Before the JOBS Act, 80 years of securities law prevented the general public from investing in private companies, like Goldenseed, at an early stage in their development. This provided the early-stage investment opportunities to only wealthy, accredited investors and those with Silicon Valley or Wall Street connections. This process is being led by Goldenseed’s consultant, Kendall Almerico, a noted securities attorney and crowdfunding expert Forbes named one of the top Regulation A attorneys and JOBS Act experts in the country.

“It’s thrilling to offer customers of Goldenseed’s high-quality products, as well as everyday consumers and investors, a chance to invest in a private United States cannabis company,” Almerico said. “This kind of investment is helping to level the playing field and democratize the investment process.”

“In addition to their shares, our investors will receive exclusive and exciting perks. We’re looking forward to announcing them soon,” said Goldie. “Our goal is to have as many people as possible share in the ownership of our company and help grow the Goldenseed brand with us.”

Currently, there are more than 200 publicly traded stocks related to the cannabis industry. Most of them involve Canadian companies or U.S. companies that do not actually grow or distribute cannabis. Goldenseed’s team believes that, when qualified by the SEC, they’ll present the first opportunity for the average investor to own a share of a private U.S. cannabis cultivator – one with a mission to create a premium cannabis lifestyle brand built on a respect for nature.

To join the growing investor waiting list and to learn more about this investment offering, visit www.OwnGoldenSeed.com.

About Goldenseed

Goldenseed, a California lifestyle cannabis and hemp brand, focuses on the cultivation, manufacturing and distribution of high-quality cannabis and hemp naturally grown in Santa Cruz, California. Deeply rooted in the California culture of artists, surfers, innovators, and diverse communities, Goldenseed aims to deliver quality products to a discerning clientele. Aiming to be a model in the cannabis industry for responsible and natural growing, harvesting, and soil-building land stewardship. www.gseed.com

*Disclaimer*
Goldenseed is “testing the waters” for a possible offering of securities under Regulation A of the JOBS Act. No money or other consideration is being solicited by the company at this time, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date.

Your indication of interest involves no obligation or commitment of any kind. If an offering statement has been filed, you may obtain a copy of the most recent version of the Preliminary Offering Circular from Kendall Almerico at Kendall A. Almerico P.A., 1440 G Street NW, Washington DC 20005 or by e-mailing hello@gseed.com. Or, you may obtain a copy of the Preliminary Offering Circular from the SEC’s website by clicking here.

Contacts

Media contacts: Evan Nicholson, James O’Hagan, Danyelle Simpkins, and Juliona Miller at Glodow Nead Communications, (415) 394-6500 or GoldenSeedPR@glodownead.com

The post Goldenseed Files with SEC to Become First Private U.S. Cannabis Grower to Allow Early Stage Investment from General Public appeared first on CannabisFN.

Flowhub Announces $23 Million in Series A Funding Led by e.ventures, Evolv Ventures and Poseidon

DENVER, Colo., Oct. 15, 2019 /PRNewswire/ — Flowhub, the leading cannabis retail management platform for modern dispensaries, today announced it has raised an oversubscribed $23 million Series A financing round led by e.ventures, Evolv Ventures — the venture fund backed by Kraft Heinz — and Poseidon, with contributions from investors 9Yards Capital, former NBA commissioner David Stern and Iqram Magdon-Ismail, the co-founder and former CEO of Venmo, among others. As one of the largest Series A rounds in the cannabis tech industry, this investment is set to position the company as the SaaS solution of choice for solving today’s complex cannabis retail challenges.

With the legal cannabis market expected to reach over $66 billion by 2025, dispensaries are expanding across the U.S. to fulfill the growing need for medicinal and adult-use cannabis. To maintain a successful, legal and compliant operation, these companies need a strategic partner like Flowhub to help them continue to scale their operations to keep up with consumer demands as well as evolving state regulations.

“What we are experiencing right now is an end to cannabis prohibition and Flowhub is on the front lines of this movement,” said Kyle Sherman, founder and CEO, Flowhub. “Every legal transaction completed with the Flowhub retail platform is a positive step forward, and we are committed to helping our customers build thriving cannabis businesses. With this investment, we will continue to automate the cannabis supply chain, retail and reporting processes and bring to market technology solutions that are not only shaping the cannabis retail business, but also driving forward the future of legalization and de-stigmatization.”

Flowhub has experienced tremendous growth over the last year, increasing revenue by 200 percent and doubling its customer base across 11 markets, which includes household brands like Cookies, Dr. Greenthumb’s, Green Dragon, Nectar and Starbuds. The company also added strategic roles to its executive team — including SaaS enterprise tech leader Dave Smith as CRO — grew its female leadership across key strategic business roles such as marketing, product management and finance and has already increased headcount by 50 percent in 2019. Flowhub also recently announced its new headquarters at the former Slack HQ near downtown Denver’s Union Station and three satellite offices to support continued expansion efforts.

“We are excited to join Flowhub at such a crucial time in the company’s overall growth journey,” said Jett Fein, partner, e.ventures. “As the demand for legal cannabis products rises across the U.S., Flowhub is focused on using technology to advance the future of the cannabis industry, and has built a cloud platform with a suite of applications that enables dispensaries to provide superior and tailored consumer retail experiences in this highly regulated industry. We support their mission and look forward to their continued success.”

On the heels of this announcement, the company debuted significant enhancements to the Flowhub platform making it even easier for customers to run and grow their dispensaries. These platform enhancements include the Stash app, the industry’s first mobile inventory management solution that maximizes efficiency and accuracy, the Cashier app for enhanced front-of-house point-of-sale capabilities with iPad/tablet compatibility, Specials engine for managing discounts across all stores and Order Ahead with integration partner Dutchie for a streamlined in-store pick up process. Flowhub also added new technology integrations with LeafBuyer and Leafly as part of its commitment to creating a robust partner ecosystem that enables customers to build their own custom cannabis tool stack.

“Cannabis is not an industry that you just jump right into,” said Emily Paxhia, managing director, Poseidon. “The compliance and regulation aspects make this a unique industry and Flowhub is one of the leading cannabis tech companies that is taking a meticulous and strategic approach. We saw the potential for Flowhub’s technology and mission early on and we’re thrilled to continue to support them in delivering the cannabis retail experience of the future.”

The $23 million of financing closed on this round brings the company’s total funding to $27 million. This marks the first cannabis tech investment from round leaders Evolv Ventures and e.ventures and is indicative of the increased appetite to bet big on a maturing market segment with an industry leader like Flowhub. With this injection of capital, the company will continue to invest in product innovation, hire top technical talent and expand its partner ecosystem with future technology integrations and collaborations through an open API approach.

To learn more or request a demo, visit www.flowhub.com.

Additional Resources

  • Watch the Green Dragon video testimonial
  • Read the platform press release
  • Request a demo

About Flowhub
Flowhub is the leading cannabis retail software company that helps modern dispensaries thrive by delivering compliance, point of sale, inventory tracking, and business intelligence data from a single, highly customizable platform. With first-to-market mobile check in and inventory management applications, Flowhub processes over one billion dollars in cannabis sales annually and empowers more than 700 cannabis retailers and their partners to grow revenue, simplify compliance, speed checkouts and manage inventory for improved consumer experiences.

 

Flowhub is a privately held company headquartered in Denver. Investors include Poseidon, Evolv Ventures, e.ventures, Green Lion Partners, Phyto Partners, Altitude and Arcadian. For more information visit flowhub.com.

SOURCE Flowhub

Related Links

https://flowhub.com

The post Flowhub Announces $23 Million in Series A Funding Led by e.ventures, Evolv Ventures and Poseidon appeared first on CannabisFN.